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John V. Ilekis, PhD; Ekaterini Tsilou, MD; Susan Fisher, PhD; Vikki M. Abrahams, PhD;
Michael J. Soares, PhD; James C. Cross, PhD; Stacy Zamudio, PhD; Nicholas P. Illsley, DPhil;
Leslie Myatt, PhD; Christine Colvis, PhD; Maged M. Costantine, MD; David M. Haas, MD;
Yoel Sadovsky, MD; Carl Weiner, MD; Erik Rytting, PhD; Gene Bidwell, PhDost adverse pregnancy outcomesAlthough much progress is being made in understanding the molecular pathways in the
placenta that are involved in the pathophysiology of pregnancy-related disorders, a
significant gap exists in the utilization of this information for the development of new drug
therapies to improve pregnancy outcome. On March 5-6, 2015, the Eunice Kennedy
Shriver National Institute of Child Health and Human Development of the National In-
stitutes of Health sponsored a 2-day workshop titled Placental Origins of Adverse
Pregnancy Outcomes: Potential Molecular Targets to begin to address this gap. Particular
emphasis was given to the identification of important molecular pathways that could serve
as drug targets and the advantages and disadvantages of targeting these particular
pathways. This article is a summary of the proceedings of that workshop. A broad number
of topics were covered that ranged from basic placental biology to clinical trials. This
included research in the basic biology of placentation, such as trophoblast migration and
spiral artery remodeling, and trophoblast sensing and response to infectious and
noninfectious agents. Research findings in these areas will be critical for the formulation
of the development of future treatments and the development of therapies for the pre-
vention of a number of pregnancy disorders of placental origin that include preeclampsia,
fetal growth restriction, and uterine inflammation. Research was also presented that
summarized ongoing clinical efforts in the United States and in Europe that has tested
novel interventions for preeclampsia and fetal growth restriction, including agents such as
oral arginine supplementation, sildenafil, pravastatin, gene therapy with virally delivered
vascular endothelial growth factor, and oxygen supplementation therapy. Strategies were
also proposed to improve fetal growth by the enhancement of nutrient transport to the
fetus by modulation of their placental transporters and the targeting of placental mito-
chondrial dysfunction and oxidative stress to improve placental health. The roles of
microRNAs and placental-derived exosomes, as well as messenger RNAs, were also
discussed in the context of their use for diagnostics and as drug targets. The workshop
discussed the aspect of safety and pharmacokinetic profiles of potential existing and new
therapeutics that will need to be determined, especially in the context of the unique
pharmacokinetic properties of pregnancy and the hurdles and pitfalls of the translation of
research findings into practice. The workshop also discussed novel methods of drug
delivery and targeting during pregnancy with the use of macromolecular carriers, such as
nanoparticles and biopolymers, to minimize placental drug transfer and hence fetal drug
exposure. In closing, a major theme that developed from the workshop was that the
scientific community must change their thinking of the pregnant woman and her fetus as a
vulnerable patient population for which drug development should be avoided, but rather
be thought of as a deprived population in need of more effective therapeutic interventions.
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placenta. Preeclampsia and fetal growth
restriction (FGR) are disorders that are
rooted in defects of early placental
development.1,2 These defects include
poor trophoblast uterine invasion,
impaired transformation of the uterine
spiral arteries to high capacity and low
impedance vessels, and/or abnormalities
in the development of chorionic villi. A
number of poor pregnancy outcomes are
associated with placental inﬂammation
because of infectious or noninfectious
causes and include early pregnancy loss,
stillbirth, and FGR.3 Signiﬁcant progress
is being made in understanding the
molecular basis of these disorders to
begin contemplating targeting the mo-
lecular pathways that are involved in
their pathophysiologic condition.
Several potential targets could be envi-
sioned readily. In the case of pre-
eclampsia, an altered balance of
circulating angiogenic/antiangiogenic
factors that are derived from the placenta
are believed to responsible for the sys-
temic vascular dysfunction that is
observed in preeclampsia.4 These factors
include an increase in the antiangiogenic
proteins such as soluble fms-like tyro-
sine kinase 1 (sFlt-1) and soluble endo-
glin, whose pathways can serve as targets
for inhibition, or a decrease in the
proangiogenic proteins such as placental
growth factor (PlGF), whose pathway
can serve as a target for stimulation. In
the case of FGR, the stimulation of the
PlGF pathway could also be targeted as aJULY 2016 American Journal of Obstetrics& Gynecology S1
Supplement Obstetrics ajog.orgmeans to increase the number of termi-
nal villi and thus increase the available
surface area for the improvement of
nutrient transfer between the maternal
blood and the growing fetus.5 Another
potential treatment to increase nutrient
transfer to the malnourished fetus is the
stimulation of the mammalian target of
rapamycin (mTOR) pathway as a means
to increase nutrient transporters.6 In the
case of placental inﬂammation, the nu-
clear factor kappa-light-chain-enhancer
of activated B cells (NF-kB) pathway,
which is a major pathway that is involved
inmediating the inﬂammatory response,
could be targeted to decrease placental
inﬂammation.7,8 A number of drugs to
target these pathways and many others
already exist in the market place or are
available at the experimental stage. A
listing of these drugs can be obtained
easily through a number of accessible
databases.9-13 In addition, a promising
pipeline of novel therapeutics are on the
horizon that include natural or synthetic
antibodies, synthetic small binding
molecules (eg, peptides and nucleic acidFrom the Pregnancy and Perinatology Branch (Dr I
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(eg, DNA gene therapy and small RNAs
(sRNAs), such as microRNAs, (miR-
NAs) and silencing RNAs (siRNAs).14-17
A major obstacle in introducing
novel pharmaceutical interventions to
improve pregnancy outcomes is based
on the general fear of inﬂicting potential
harm, particularly to the fetus, that may
result in either short- or long-term
deleterious effects. Understandably, a
very cautious direction is taken, and
most studies involve either the evalua-
tion of off-label drugs with a very safe
history or dietary supplementation for
use in pregnancy. Although extreme
caution is warranted, the current chal-
lenge is to overcome the overbearing
reticence of doing harm that unduly
hinders the development and testing of
new and novel approaches to improve
pregnancy outcomes. The ﬁrst step is to
test potential drug therapies for their
safety and efﬁcacy in animal models,
which then, in turn, can lead to human
studies. A number of important factors
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JULY 2016chance of a successful therapeutic agent.
These include that the ideal therapeutic
agent should be highly speciﬁc to a key
step in the targeted pathway and that it
acts as far down stream as possible to
produce the desired effect, thus mini-
mizing unfavorable upstream-mediated
cascading events. Furthermore, the
ideal therapeutic should avoid or mini-
mize maternal and fetal systemic effects.
Thus, selectively targeting the placenta
and optimizing the dosage would be
important considerations. In this regard,
placental homing molecules coupled to a
delivery system that contains the thera-
peutic agent (such as nanoparticles,
synthetic peptides, liposomes, exo-
somes) and cell-speciﬁc DNA expression
vectors show exciting promise to elimi-
nate or minimize any deleterious collat-
eral effects for either the mother or
fetus.18 The timing of the delivery of the
therapeutic agent is also another
important consideration because the
placenta is a developing organ with
certain pathways that take critical roles at
different developmental stages. Thus, the
modulation of a particular molecular
pathway at an inappropriate time win-
dow may result in deleterious effects by
interfering with the normal develop-
mental trajectory. For example, villous
maturation undergoes an orderly devel-
opmental process that is orchestrated by
the angiogenic factors vascular endo-
thelial growth factor (VEGF) and
PlGF.1,5,19 VEGF is involved in early
villous formation and drives primary
and secondary branching angiogenesis.
This is followed by nonbranching
angiogenesis and the formation of the
tertiary terminal villi, principally under
the control of PlGF. Primary and sec-
ondary branching angiogenesis generally
is complete by approximately 20 weeks
of gestation, after which tertiary termi-
nal villi formation predominates and
continues to term.1 Thus, in a hypo-
thetical situation for the treatment of
FGR, stimulating the PlGF pathway too
early (ie, before the adequate completion
of primary and secondary branching
angiogenesis) conceivably could result in
malformation of normal villous struc-
ture and function. Another factor to
consider is the required exposure time to
TABLE 1
Workshop session themes and their respective topics
I. Review of placental development and function in the context of the molecular mechanisms
and pathways
Human trophoblast differentiation and placentation
Innate immune function of human trophoblast
Modeling trophoblast differentiation and placentation in the rat
Modeling trophoblast differentiation and placentation in the mouse
II. Potential “drug” targets of important placental molecular pathways throughout placental
development in relation to pregnancy disorders
Placental hypoxia as a therapeutic molecular target
Is fetal growth a feasible target for placental intervention?
Targeting oxidative/nitrative stress and mitochondrial dysfunction in placenta to relieve
adverse pregnancy outcomes
III. Identify potentially useful or experimental drugs to target important molecular pathways
Challenges and advantages of rescuing and repurposing
Effect of pregnancy on drug pharmacokinetics and pharmacodynamics
From bench to bedside: processes and pitfalls translating research findings into practice
paradigms
IV. Evolving technologies for placental specific “therapeutic/drug” delivery
Trophoblastic nanovesicles, microRNA, and their targets aberrant regulation of myometrial
contractility by maternal cell-free plasma RNA of placental origin: screening and therapeutic
implications
Maternally sequestered delivery systems for prevention of fetal drug exposure
Novel therapeutic interventions and delivery systems
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desired effect. Will the therapeutic agent
be required to be administered contin-
uously or only for a short duration of
time? In the aforementioned FGR treat-
ment scenario, how long of a time period
is required to increase and maintain the
number of terminal villi? Once formed,
will the morphologic change remain
permanent, or will the induced
morphologic change regress if the stim-
ulus is not continued? Therefore, speci-
ﬁcity, dosage, delivery, timing, and
length of exposure are some of the key
factors in the development of a success-
ful therapeutic agent.
Although much progress is being
made in understanding the molecular
pathways in the placenta that are
involved in the pathophysiologic condi-
tion of pregnancy-related disorders, a
signiﬁcant gap exists in using this in-
formation for developing new drug
therapies to improve pregnancy
outcome. To address this concern, the
Eunice Kennedy Shriver National Insti-
tute of Child Health and Human
Development of the National Institutes
of Health sponsored a 2-day workshop
on March 5-6, 2015, titled “Placental
Origins of Adverse Pregnancy Out-
comes: Potential Molecular Targets,” to
discuss and reﬂect on placental drug
targeting to improve pregnancy out-
comes. The workshop brought together
leaders in the ﬁeld to present and discuss
their particular area of research and
stimulate dialogue in the context of the
theme of the workshop. The goals of the
workshop were (1) to present the state of
the science with respect to the molecular
mechanisms that are involved in
placentation, (2) to identify potential
molecular pathways and developmental
time windows for targeting effective
“drug” interventions to avoid placenta-
tion defects in early pregnancy and
circumvent placental defects later in
pregnancy, and (3) to identify major
research gaps in our understanding of
placental molecular pathways that lead
to adverse pregnancy outcomes. This
article summarizes the proceedings of
that workshop. The overall objective of
the workshop was to stimulate the
research community to better apply theknowledge that is obtained from the
laboratory bench for use at the bedside.
A summary of the research topic that was
covered by each participant is presented
along with their opinions on current and
future opportunities and research gaps.
The article is organized according to 4
session themes. The session themes and
their respective topics are listed in
Table 1. Table 2 is a key to abbreviated
scientiﬁc terms that are used commonly
throughout the article.
Review of placental development and
function in the context of molecular
mechanisms and pathways
Human trophoblast differentiation
and placentation (Susan Fisher,
University of California San Francisco)
Cytotrophoblast differentiation establishes
the anatomy of the human maternal-fetal
interface. The complex cellular architec-
ture at the boundary between theJULY 2016 Aplacenta and uterus is governed, in
large part, by the cytotrophoblast dif-
ferentiation pathway that enables
invasion.20,21 With regard to the
anatomic arrangement, placental cyto-
trophoblasts emigrate from anchoring
villi and join cell columns that serve as
conduits to the uterine wall (Figure 1).
Within the uterus, the cytotrophoblasts
invade nearly its entirety, normally
stopping one-third of the way through
the muscle layer. Within the decidua,
interstitial cytotrophoblasts interact
with specialized populations of maternal
immune cells that are allowed to enter
this compartment. During invasion,
the cells also remodel the uterine circu-
lation, primarily by targeting the spiral
arteries. They transform the walls of
these vessels. Endovascular cytotropho-
blasts replace the endothelium and
intercalate within the smooth muscle
cells of the tunica media. This processmerican Journal of Obstetrics& Gynecology S3
TABLE 2
Abbreviations for commonly used scientific terms [in file but NOT
EDITED]
Abbreviation Description
AB apoptotic bleb
aPL antiphospholipid antibodies
APOA4 apolipoprotein a-iv
C19MC chromosome 19 miRNA cluster
CaO2 arterial oxygen content
CARD caspase activation and recruitment domain
Caþþ calcium
CFP cell-free plasma
CO cardiac output
CTB cytotrophoblast
CYP cytochrome P
DAMP damage associated molecular pattern
DNA deoxyribonucleic acid
dsRNA double-stranded ribonucleic acid
EDH endothelium derived hyperpolarizing
EGFR epidermal growth factor receptor
ELP elastin-like polypeptide
EPO erythropoietin
FDA Food and Drug Administration
FGR fetal growth restriction; also known as IUGR
FOA funding opportunity announcement
GDM gestatoinal diabetes mellitus
GLUT glucose transporter
GPx glutathione peroxidase
GRO-a melanoma growth stimulating activity, alpha
HIF hypoxia inducible factor
HIV human immunodeficiency virus
HLA human leukocyte antigen
HMGB1 high mobility group B1
iE-DAP gamma-D-glutamyl-meso-diaminopimelic acid
IFNGR interferon-gamma receptor
IGF insulin-like growth factor
IL interleukin
IL interferon
IRAK interleukin-1 receptor associated kinase
IRF interferon regulatory factor
IUGR intrauterine growth restriction (also known as FGR)
LPS lipopolysaccharide
m meters
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high-resistance uterine arteries into
high-capacitance/low-resistance chan-
nels that perfuse the surface of the
placenta, which is comprised of multi-
nucleated syncytiotrophoblast, which is
a transport epithelium. Thus, they can
respond to the ever-increasing demands
of the offspring for maternal blood over
the course of pregnancy.
At a molecular level, cytotrophoblast
invasion of the uterus is as remarkable as
the unique behaviors that the cells
exhibit. The progenitors, which are
attached to the trophoblast basement
membrane of the chorionic villi, express
an adhesion molecule repertoire that is
typical of epithelial cells (eg, epithelial-
cadherin and integrin a6/b4). As they
enter the columns, the emigrating cyto-
trophoblasts undergo a stereotypical
transformation. They down-regulate
those that are typical of an epithelial
monolayer and up-regulate receptors
that enable invasion (eg, aV family
members; Figure 2), vascular endothelial
cadherin and integrin a1/b1. Remark-
ably, the end result of this transformation
is vascular mimicry in which cyto-
trophoblasts of epithelial origin express a
broad repertoire of adhesion molecules,
growth factors, ephrin receptors and
their cognate ligands (ephrins), and
notch family members that typically are
associated with endothelium and the
muscular tunica media of vessels.
Preeclampsia is associated with abnormal
cytotrophoblast invasion and differ-
entiation.Many investigators believe that
preeclampsia (the sudden onset of
maternal high blood pressure, protein-
uria, and edema) occurs in 2 stages.22
The ﬁrst stage involves shallow cyto-
trophoblast invasion of the uterus, which
was ﬁrst described by Brosens et al.23,24
Failed transformation of spiral arteries
appears to be critical and leads to
hypoperfusion of the placenta and
oxidative stress.25 The second stage in-
cludes overactive maternal immune
responses. Although these pathways are
associated most commonly with pre-
eclampsia, similar diseases have been
described in a subset of preterm labor/
birth cases.21 The causes are under
TABLE 2
Abbreviations for commonly used scientific terms [in file but NOT
EDITED] (continued)
Abbreviation Description
mmHg millimeters mercury
MAL myelin and lymphocyte
MCP-1 monocyte chemoattractant protein-1
MDP muramyl dipeptide
miRNA micro-ribonucleic acid
mRNA messenger RNA
MR mass restricted
mTOR mammalian target of rapamycin
MV microvesicle
MVB multivesicular body
NADPH myeloid differentiation primary response gene 88
NCATS National Center for Advancing Translational Sciences
NF-kB nuclear factor kappa beta
NGS next generation sequencing
NIH National Institutes of Health
NK natural killer
NLR nod-like receptor
NO nitric oxide
Nod nucleotide oligomerization domain protein
NRP1 neuropilin-1
NTU new therapeutic uses
O2 oxygen
PAMP pathogen-associated molecular pattern
PaO2 partial pressure of arterial oxygen
PD pharmacodynamic
PDG peptidoglycan
PE preeclampsia
PK pharmacokinetic
PI3K/Akt phosphatidylinositol-3-kinase/protein kinase B
PlGF placental growth factor
PO2 partial pressure of oxygen
PPROM preterm premature rupture of membranes
Prl prolactin
PRR pattern recognition receptors
PTL/B preterm labor/birth
PTB preterm birth
Kþ potassium
RICK receptor-interacting protein-like interacting caspase-
like apoptosis regulatory protein kinase
Ilekis. Potential placental molecular therapeutic targets. Am J Obstet Gynecol 2016. (continued)
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preeclampsia are associated with failed
cytotrophoblast transformation into
vascular-like cells coincident with
shallow uterine invasion.26 For example,
placental cells that enter the uterine wall
fail to down-regulate epithelial cadherin
and to up-regulate vascular epithelial
cadherin. They also misexpress a broad
array of angiogenic and/or vasculogenic
factors. These include VEGF family
members. For example, invasive cyto-
trophoblasts from preeclampsia preg-
nancies fail to stain with anti-VEGF A,
which their normal counterparts express
in abundance. In addition, they release
higher amounts of soluble VEGFR1
(sFlt-1),27 as do syncytiotrophoblasts.28
Increasing circulating levels of sFlt-1
and other angiogenic factors (such as
endoglin) cause a preeclampsia-like
syndrome in animal models.29,30 Thus,
there has been a great deal of interest in
whether or not circulating levels of
molecules that could have negative ef-
fects on the maternal vasculature can be
used to predict and/or diagnose pre-
eclampsia.31-33
Is abnormal placental production of
angiogenic/vasculogenic factors a cause
or consequence of preeclampsia? As yet,
there are no deﬁnitive answers to this
question. However, alternative explana-
tions abound. For example, particular
combinations of maternal natural killer
(NK) cell expression of killer cell
immunoglobulin-like receptors that
recognize the certain major histocom-
patibility complex molecule, human
leucocyte antigen C, on invading cyto-
trophoblasts increase the risk of pre-
eclampsia.34 Surprisingly, a recent study
showed that, on isolation from pre-
eclampsia placentas, cytotrophoblast
gene expression (eg, growth hormone
[GH] 2, corticotrophin-releasing hor-
mone, kiss-1 metastasis-suppressor 1,
semaphoring 3B, and several pregnancy-
speciﬁc beta-1-glycoproteins) is nor-
malized,35which suggests that the defects
are reversible and that pursuit of thera-
pies is warranted.
Current opportunities. As compared with
other medical conditions, very little
attention has been paid to therapeutic/JULY 2016 American Journal of Obstetrics& Gynecology S5
TABLE 2
Abbreviations for commonly used scientific terms [in file but NOT
EDITED] (continued)
Abbreviation Description
RNA ribonucleic acid
ROS reactive oxygen species
sFlt-1 soluble fms-like tyrosine kinase 1 (also known as
soluble VEGFR1)
SOD superoxide dismutase
sPTB spontaneous preterm birth
STB syncytiotrophoblast
sRNA small ribonucleic acid
siRNA silencing ribonucleic acid
ssRNA single-stranded ribonucleic acid
T1 translational spectrum 1, translation of animal and
bastic research into humans
T2 translational spectrum 2, translation of clinical
research findings to practice
TBK-1 tank-binding kinase 1
TLR toll-like receptor
TNFa tumor necrosis factor; alpha
TRAF TNF receptor associated factor
TRAM trif-related adaptor molecule
TRIF tir-domain-containing adapter-inducing interferon-b
TS trophoblast stem
uNK uterine natural killer
VEGF vascular endothelial growth factor
VEGFR VEGF receptor
Ilekis. Potential placental molecular therapeutic targets. Am J Obstet Gynecol 2016.
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great obstetric syndromes. In this
context, pregnancy complications are
the equivalent of “orphan” diseases, not
because they are rare conditions but
because there is very little monetary
incentive for taking on the risk that
treating pregnant women entails. How-
ever, there are compelling reasons to
shift this paradigm.Most of the common
diseases that derail human pregnancy
affect the placenta. Many involve either
fetal or maternal cells that reside within
the uterine wall. Thus, it is likely that
effective therapies could be designed to
target these cells without crossing the
placenta and reaching the embryo/fetus.
For example, many kinds of drugs (eg,S6 American Journal of Obstetrics& Gynecologyantibodies, small molecules) that target
particular vulnerabilities (eg, vascular
and/or immune functions) could be
formulated as derivatives that prevent
syncytiotrophoblast transport, thus
reducing the risk of untoward embry-
onic/fetal events. As a ﬁrst step, this
general strategy could be tried with
agents that are already used to treat
pregnant women (eg, tumor necrosis
factorealpha inhibitors that work, in
part, by blocking the activation of
endothelial and immune cells that this
cytokine produces. For example, certo-
lizumab (a pegylated fragment antigen-
binding fragment of a humanized
monoclonal antibody that inhibits
tumor necrosis factorealpha), whichJULY 2016does not cross the placenta, could be
evaluated in women who have a high
risk of pregnancy loss because of the
effects of this cytokine (eg, inﬂammatory
and thrombotic placental lesions) in
the setting of autoimmune disorders
such as antiphospholipid antibody syn-
drome. 36
Future opportunities.Until recently, it
was thought that placental interactions
with the mother occurred at a cellular
level (eg, invasive cytotrophoblasts and
maternal immune cells within the uter-
ine wall) or involved soluble proteins
(eg, human chorionic gonadotropin).
However, this paradigm is shifting rapidly.
Free fetal DNA, which circulates in
maternal blood,37 is being used as a
noninvasive means of prenatal genetic
diagnoses.38 It is possible that circulating
cell-free RNA could be used as a com-
plementary method and/or as a means of
gaining additional information.39 Also,
like many cancer cells, the placenta ap-
pears to release a complex repertoire of
extracellular vesicles the cargo of which
could have major effects on numerous
maternal cells, tissues, and organs.40,41
Thus, obtaining an in-depth under-
standing of the types and content of
placental extracellular vesicles will in-
crease our understanding of their func-
tions. For example, it would be interesting
to determine how their contents and tar-
gets change over the course of gestation
and the impact of the commonpregnancy
complications, which include pre-
eclampsia and preterm labor/birth, on
the normal trajectory. Ultimately, this
important information could lead to
several types of clinical applications (eg,
extracellular vesicles could be used to
infer important aspects of placental
functions). Other possibilities include
therapies that target extracellular vesicles
or take advantage of this system of inter-
cellular communication for drug delivery.
Scientiﬁc gaps in relation to drug targe-
ting. A myriad of questions remain
to be answered about mechanisms
that are central to the success of
normal pregnancy and go awry in preg-
nancy complications. For example,
maternal tolerance of hemiallogeneic
FIGURE 1
A schematic drawing of the maternal-fetal interface in human pregnancy
Mononuclear placental cytotrophoblasts invade the uterine wall and its resident vasculature (right
panel). During this process, they transform spiral arteries into wide-bore vessels that perfuse the
placenta. Its tree-like chorionic villi are covered by multinucleated syncytiotrophoblasts, which
transport a variety of substances to and from the fetus, enabling normal fetal growth.
Reprinted with permission from Romero et al.21
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explanation. Therefore, it is very difﬁ-
cult to devise targeted therapies for
pregnancy disorders, from infertility to
preeclampsia, that are thought to have
an immune cause or component. Like-
wise, lack of knowledge impedes strate-
gies for dampening the maternal
immune response to infections during
pregnancy, which can lead to preterm
labor/birth. In cases of the latter syn-
drome with an unknown cause, thera-
pies lag because we do not understand
the pathways that normally trigger
normal labor and birth at the end of
pregnancy. Finally, preeclampsia ap-
pears to arise because of profound
miscommunication between the pla-
centa and the mother. The development
of drugs that intercept or redirect these
signals will require a molecular dissec-
tion of their components.
Innate immune function of human
trophoblast (Vikki M. Abrahams, Yale
University)
Background. Placental trophoblast cells
can sense and respond to a variety
of infectious pathogen-associated mo-
lecular patterns that are expressed
by microbes, as well as noninfectious
host-derived damage-associated molec-
ular patterns (DAMPs) through their
expression of innate immune pattern
recognition receptors (PRRs).42,43
Depending on the trigger or receptor
that is activated, the trophoblast may
mount either a regulated protective
response that helps to maintain and
promote a healthy pregnancy or a
damaging response that might impact
pregnancy outcome adversely (Figure 3).
Moreover, expressions of some tropho-
blast PRRs are regulated gestationally,
which further impacts the placental
response.44
PRRs. Twomajor families of PRRs are the
Toll-like receptors (TLRs) and the Nod-
like receptors (NLRs). TLRs are trans-
membrane receptors, which allows for
the sensing of PAMPs or DAMPs either at
the cell surface or within endosomal
compartments.45 There are 10 human
and 12 murine TLRs, each with distinct
speciﬁcities.46 TLR4 recognizes Gram-negative bacterial lipopolysaccharide.
TLR2, in cooperationwith its coreceptors
TLR1, TLR6, or TLR10, recognizes
Gram-positive bacterial peptidoglycan
and lipoproteins. TLR3 senses viral
double-stranded RNA; TLR5 senses
bacterial ﬂagellin. Mouse TLR7 and hu-
man TLR8 sense viral single-stranded
RNA, and TLR9 senses bacterial DNA.46
Four adapter proteins are involved in
TLR signaling: myelin and lymphocyte
protein 88 (MyD88), TIR-domaine
containing adapter-inducing interferon-
beta (TRIF), myelin and lymphocyte
protein (Mal), and TRIF-related adaptor
molecule.47,48 TLR2 and TLR4 signal
through MyD88/Mal. TLR4 can also
signal through TRIF/ TRIF-related
adaptor molecule. TLR3 signals through
TRIF; all other TLRs signal through
MyD88 alone.47,48 Downstream, TLR/
MyD88 signaling activates NFkB; TLR/
TRIF activates Tank-binding kinase-1
and interferon regulatory factor 3 that
leads to a type I interferon response
(Figure 4).48,49
NLRs are cytoplasmic-based PRRs
that provide an intracellular recognition
system for sensing microbe-associated
pathogen-associated molecular pattern
(PAMP) or as will be discussed, DAMPs.JULY 2016 ANLRs can synergize with TLRs for a
greater response or provide a compen-
satory system for when TLR signaling
is absent or reduced.50,51 The NLR
proteins, Nod1 and Nod2, recognize
the peptidoglycan peptides Gram-
negative bacterial gamma-D-glutamyl-
meso-diaminopimelic acid (iE-DAP-)
and muramyl dipeptide (MDP) that is
expressed by all bacteria, respectively.
Both Nod1 and Nod2 signal through the
common adapter protein receptor-
interacting protein-like interacting
caspase-like apoptosis regulatory protein
kinase (RICK) to induce inﬂamma-
tion.52 Another NLR called NACHT,
leucine-rich repeat protein and the
NLR, Nalp3, are involved in mediating
the production of the proinﬂammatory
cytokine interleukin (IL)-1b.53,54
Because IL-1b has the potential to be
damaging, its regulation is tightly
controlled. Indeed, IL-1b is an important
mediator of preterm birth102-105 and
perinatal brain injury106-109 and can
trigger the production of other proin-
ﬂammatory cytokines and chemokines
through the IL-1 receptor in a similar
manner to TLRs.55 Indeed, delivery
of a synthetic peptide to pregnant
mice that is a selective IL-1 receptormerican Journal of Obstetrics& Gynecology S7
FIGURE 2
Phenotypic transformation of cytotrophoblast during uterine invasion
Cytotrophoblasts switch their expression of integrin aVb family members as they invade the uterine
wall. Sections of the maternal-fetal interface at various weeks of gestation (18-22) were double
stained with anti-cytokeratin to mark A, C, E, G, cytotrophoblasts and B, D, F, H, anti-aVb5, anti-
aVb6, or anti-aVb3. aVb5 was detected on cytotrophoblasts in floating (data not shown) and
anchoring villi, but not in other locations. aVb6 was detected on villous cytotrophoblasts at sites of
column formation and in the first cell layer of the column. aVb3 was up-regulated in the distal
portions of the columns and on endovascular cytotrophoblasts that lined the maternal blood vessels.
AV, anchoring villi; b3, anti-aVb3; b5, anti-aVb5; b6, anti-aVb6; BV, blood vessels; CK, anti-cytokeratin; EC, endothelial cell.
Reprinted with permission from Zhou et al.134
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lipopolysaccharide-induced preterm
birth.56 Unlike most other cytokines, IL-
1b production involves a 2-step process.S8 American Journal of Obstetrics& GynecologyThe ﬁrst step requires induction of
proeIL-1b expression. This is triggered
through signals like TLRs (signal 1).
Once expressed, proeIL-1b can beJULY 2016cleaved into its active secreted form.57
This second step (signal 2) is mediated
typically by the Nalp3 inﬂammasome a
protein complex consisting of Nalp3,
apoptosis-associated speck-like protein
that contains a caspase recruitment
domain (CARD) and caspase-1.53 Once
the inﬂammasome has assembled,
caspase-1 is activated and processes
proeIL-1b into its secreted form
(Figure 5).57 Although the Nalp3 inﬂam-
masome is the best characterized, there
are a number of inﬂammasomes: Nalp1/
apoptosis-associated speck-like protein
containing a CARD; absent in melanoma
2 protein A; NLR family, CARD domain
containing 4 protein; and interferon
gamma-inducible protein 16.112 Further-
more, Nod proteins can mediate IL-1b
production independent of the inﬂam-
masome. For example, Chlamydia tra-
chomatis infection of human trophoblast
induces IL-1b via Nod 1.113
Trophoblast sensing of bacteria. Bacterial
components such lipopolysaccharide,
iE-DAP, and MDP, at high concentra-
tions, trigger mild proinﬂammatory
cytokines/chemokines (IL-8, IL-6,
monocyte chemoattractant protein-1
[MCP-1], and melanoma growth stim-
ulating activity, alpha [GRO-a]) re-
sponses in ﬁrst trimester trophoblast
cells through TLR4, Nod1, and Nod2,
respectively, although lower, more
physiological doses, are unable to induce
this trophoblast inﬂammation.58-61
Third trimester trophoblast cells lack
Nod2 and thus responses to MDP are
altered.62 Similarly, third trimester syn-
cytiotrophoblast cells can generate a
strong inﬂammatory response to lower
lipopolysaccharide doses. Thus, there
are differential sensitivities of tropho-
blast cells to bacterial components
across gestation.63 This dose dependency
and role for TLRs and NLRs is
reﬂected in vivo. In pregnant mice,
high-dose lipopolysaccharide induces
placental and uterine inﬂammation
and subsequent preterm birth.64 TLR4
deﬁcient mice are protected against
bacterial and lipopolysaccharide-
induced preterm birth,65,66 and block-
ing TLR4 in nonhuman primates
prevents lipopolysaccharide-induced
FIGURE 3
Innate immune sensing by the trophoblast
Trophoblast cells sense infectious pathogen-associated molecular patterns that are expressed by
bacteria, viruses, fungi, and parasites through their expression of Toll-like receptors and Nod-like
receptors. Through these receptors, trophoblast cells also mount responses to noninfectious
host-derived damage-associated molecular patterns, such as uric acid, high mobility group B1,
glucose, and certain autoantibodies. Trophoblast expression of some Toll-like receptors and Nod-like
receptors are regulated across gestation and cell subtype. Depending on the trigger, receptor
activated, and type of signaling pathway used, the trophoblast may mount either a regulated pro-
tective response that helps to maintain and promote a healthy pregnancy or a damaging pathologic
response that might impact pregnancy outcome adversely.
PAMPs, pathogen-associated molecular patterns; DAMPs, damage-associated molecular patterns; HMGB1, high mobility group B1;
NLRs, Nod-like receptors; TLRs, Toll-like receptors.
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dose iE-DAP also induces inﬂammation
at the maternal-fetal interface and pre-
term birth.62 However, low-dose lipo-
polysaccharide can trigger preterm birth
in mice on a pathologic background,
such as an active viral infection67,68 or
IL-10 deﬁciency.69,70 Thus, although
TLRs and NLRs appear to be involved
in preterm birth in response to bacterial
components, in normal early pregnancy,
there appears to be some tolerance
towards certain triggers, such as lipo-
polysaccharide, that may always be pre-
sent at the maternal-fetal interface.71,72
Furthermore, although bacteria can
induce preterm birth,73,74 additional
signals, such as a virus, may further
sensitize the placenta to these bacterial
signals. 67,68
Gram-positive bacterial peptido-
glycan, which activates TLR2 in associ-
ation with TLR1, TLR6, or TLR10,
triggers a very different response in hu-
man ﬁrst-trimester trophoblast cells
compared with term trophoblast. At
term, peptidoglycan activates these cells
to produce IL-8.75 However, in ﬁrst-
trimester trophoblast cells, instead of
activating the classic inﬂammatory
cascade, peptidoglycan through TLR1,
TLR2, and TLR10 induces apoptosis and
down-regulates the cell’s basal cytokine/
chemokine expression. Moreover, this
apoptotic response is prevented by the
ectopic expression of TLR6, which is
absent in the ﬁrst-trimester tropho-
blast.58,76-78 Similarly, delivery of pepti-
doglycan early in gestation induces
placental apoptosis without evidence of
inﬂammation,76 although delivery later
in gestation triggers preterm birth.79
Viral sensing by the trophoblast. The viral
sensors, TLR3 and TLR8, that recognize
viral double-stranded RNA and single-
stranded RNA, respectively, mediate a
rapid, robust chemokine/cytokine (IL-6,
IL-8), type I interferon, and antiviral
response in human ﬁrst-trimester
trophoblast.80-82 Furthermore, inde-
pendent of TLR8, viral single-stranded
RNA also induces trophoblast expres-
sion of IL-1b, antiviral factors, and the
induction of apoptosis.82 This placental
single-stranded RNAeinduced responseis mirrored in vivo without triggering
preterm birth.82 In contrast, viral
double-stranded RNA induces preterm
birth through TLR379,83; other groups
have reported preeclampsia-like symp-
toms in viral double-stranded RNA-
treated mice.84
Trophoblast activation by DAMPs. In
addition to understanding how the
trophoblast responds to PAMPs, the
impact of DAMPs on trophoblast func-
tion has been investigated. DAMPs are
host-derived factors that are either not
usually released from cells or tissues or, if
present in the extracellular space, are
normally at low levels. The DAMP, high-
mobility group B1 (HMGB1) can be
released, passively from damaged cells or
actively in response to inﬂammatory
triggers and can mediate inﬂammatory
responses via TLR2, TLR4, or receptor
for advanced glycation end products 85
(Figure 4). HMGB1 levels are increased
in the amniotic ﬂuid from patients with
preterm birth or preterm premature
rupture of membranes and intrauterine
infection,86 in fetal membranes fromJULY 2016 Apatients with preterm labor and preterm
premature rupture of membranes,87 and
in serum from pregnancies that are
complicated by either preeclampsia or
reduced fetal movements.88,98 Term
trophoblast cells that are treated with
HMGB1 secrete signiﬁcantly increased
levels of IL-1b, IL-6, and monocyte
chemoattractant protein-1; however,
mechanistic studies are needed to show
which receptors and signaling pathways
are activated by this DAMP.89 One type
of DAMP that has been characterized
extensively is the antiphospholipid
antibody (aPL), which are autoanti-
bodies that speciﬁcally target the
trophoblast by binding surface beta2
glycoprotein 1.90 These autoantibodies
activate human ﬁrst-trimester tropho-
blast TLR4 that results in inﬂammatory
IL-8 and IL-1b secretion (Figure 4).91,92
Downstream of TLR4, aPLs induce
endogenous uric acid, which is another
DAMP that speciﬁcally activates the
Nalp3 inﬂammasome,93 which medi-
tates proeIL-1b processing and secre-
tion (Figure 5).92 In parallel, aPL via
TLR4 induces the expression of themerican Journal of Obstetrics& Gynecology S9
FIGURE 4
Toll-like receptor signaling
Toll-like receptors are transmembrane receptors that mediate the sensing of pathogen-associated
molecular patterns expressed by microorganisms. Toll-like receptor 2, in cooperation with its cor-
eceptors Toll-like receptors 1, 6, or 10, recognizes Gram-positive bacterial peptidoglycan. Toll-like
receptor 4 recognizes Gram-negative bacterial lipopolysaccharide. Toll-like receptors 3 and 7/8
sense viral double-stranded RNA and single-stranded RNA, respectively. Toll-like receptor 5 senses
bacterial flagellin, and Toll-like receptor 9 senses bacterial cytosine-guanine dinucleotideerich DNA
regions. Four adapter proteins are involved in Toll-like receptor signaling: MyD88, TRIF, Mal, and
TRAM that trigger downstream pathways that lead to either nuclear factor kappa-light-chain-
enhancer of activated B cells activation and subsequent cytokine/chemokine production or IRF-3/
IRF-7 activation that leads to a type I interferon response. Some Toll-like receptors also sense
host-derived damage-associated molecular patterns. Toll-like receptors 2 and 4 can sense high
mobility group B1 protein; Toll-like receptor 4 can be activated by antiphospholipid antibodies. Refer
to Table 2 for the key to undefined abbreviations.
aPLs, antiphospholipid antibodies; CpG, cytosine-guanine dinucleotide; DAMPs, damage-associated molecular patterns; dsRNA,
double-stranded RNA; HMGV1, high mobility group B1; IFNs, interferon; IRAK, interleukin-1 receptor-associated kinase; IRF, interferon
regulatory factor; LPS, lipopolysaccharide; Mal, myelin and lymphocyte; MyD88, myeloid differentiation primary response protein 88;
NFkB, nuclear factor kappa-light-chain-enhancer of activated B cells; PAMPs, pathogen-associated molecular patterns; PDG, pepti-
doglycan; ssRNA, single-stranded RNA; TBK, tank-binding kinase; TLR, Toll-like receptor; TRAF, tumor necrosis factor receptor-
associated factor; TRIF, tir-domainecontaining adapter-inducing interferon-b.
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secretion by activating TLR8.94,95 Thus,
aPL, through TLR4, induces endogenous
secondary messengers that subsequently
activate other trophoblast innate im-
mune PRRs. Hyperglycemic levels of
glucose have similar effects on these cells,
which suggests that overt pregestational
diabetes mellitus may impact placental
inﬂammation and function early in
pregnancy. Excess glucose induces a
proinﬂammatory cytokine/chemokine
proﬁle (IL-1b, IL-6, IL-8, GRO-a,
regulated on activation normal T cell
expressed and secreted, chemokine, and
granulocyte colony stimulating factor).
Moreover, the IL-1b response isS10 American Journal of Obstetrics& Gynecologyassociated with elevated uric acid and is
dependent on the activation of the Nalp3
inﬂammasome.96 Elevated serum uric
acid has been associated with high-risk
pregnancies, such as those complicated
by preeclampsia, gestational hyperten-
sion, cases of reduced fetal movements,
or obstetric aPL syndrome.92,97-99 Thus,
rather than simply correlating levels with
disease, uric acid can act as a direct
mediator of trophoblast inﬂammasome
activation and placental inﬂammation,93
which suggests that it may play a path-
ologic role. Furthermore, that those
host-derived noninfectious triggers
(such as uric acid, glucose and aPL) can
activate the inﬂammasome indicates thatJULY 2016this mechanism is not involved only in
microbial-induced inﬂammation, but
also in sterile-induced inﬂammation.
Current opportunities. Inhibiting PRR
activation to prevent infection-
associated preterm birth has been
considered. A TLR4 antagonist pre-
vented lipopolysaccharide-induced pre-
term uterine contractility in nonhuman
primates100 and knockout mice for TLR,
or associated adapter proteins are resis-
tant to microbial and PAMP-induced
preterm birth.83,101 Similarly, because
IL-1b is amediator of pretermbirth102-105
and fetal brain injury,106-109 studies
have focused on using IL-1 receptor an-
tagonists or selective IL-1 receptor
modulators to prevent these adverse
outcomes.110,111 Preventing the upstream
induction of IL-1b by inhibiting placental
inﬂammasome activitymay also serve as a
potential target for the prevention of
adverse pregnancy outcomes.
Future opportunities. Because uric acid
mediates placental inﬂammasome func-
tion,92,93,96 currently available drugs that
inhibit xanthine oxidase, such as allo-
purinol or febuxostat, may provide
potential avenues to explore. However,
this is only 1 mechanism by which IL-1b
production can arise; there are a number
of other inﬂammasomes that uric
acid may not activate112 and none
inﬂammasome-mediated pathways,113
all of which could be possible targets.
Similarly, as we expand our knowledge
about the role of miRNAs in the medi-
ation and regulation of placental func-
tion and PRR activity, we can begin to
consider these as potential therapeutic
targets.
Scientiﬁc gaps. Together, the studies dis-
cussed herein demonstrate that the
placenta is immunologically functional,
with the trophoblast able to generate
speciﬁc and diverse innate immune-like
responses through their expression of a
range of PRRs. However, the type of
response is highly dependent on the
stimuli, the receptors expressed and
activated, the downstream signaling
pathways involved, and the timing of
gestation. Indeed, although many of the
FIGURE 5
Nod-like receptor signaling
Nod-like receptors are cytoplasmic proteins that sense pathogen-associated molecular patterns.
Nod1 recognizes bacterial iE-DAP, and Nod2 senses bacterial muramyl dipeptide. Both Nod1 and
Nod2 signal through the adapter protein receptor-interacting protein-like interacting caspase-like
apoptosis regulatory protein kinase to induce nuclear factor kappa-light-chain-enhancer of acti-
vated B cells activation and subsequent cytokine/chemokine production. Nalp3 recruits ASC and
caspase-1 to form the inflammasome. Once the inflammasome has assembled, caspase-1 is
activated and processes pro-IL-1b into its active, secreted form. Refer to Table 2 for the key to
undefined abbreviations.
ASC, apoptosis-associated speck-like protein containing a caspase recruitment domain [CARD]; DAMP, damage-associated molecular
pattern; IL, interleukin;MDP, muramyl dipeptide; Nalp, protein complex consisting of Nalp3, apoptosis-associated speck-like protein that
contains a [CARD] and caspase-1; NFkB, nuclear factor kappa-light-chain-enhancer of activated B cells; NLRs, Nod-like receptors;
PAMPs, pathogen-associated molecular patterns; Pro-IL, precursor protein of interleukin; RICK, receptor-interacting protein-like
interacting caspase-like apoptosis regulatory protein kinase.
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outcome triggered by PAMPs and
DAMPs may be common, the upstream
mechanisms are often quite distinct.
These challenges for drug discovery and
applications highlight the need for a
greater understanding of the precise
molecular pathways that are involved in
placental sensing of infectious and
noninfectious triggers.
Modelling trophoblast differentiation
and placentation in the rat (Michael J.
Soares, University of Kansas)
Background. Fundamental to the estab-
lishment of pregnancy and formation of
the hemochorial placenta is remodeling
and restructuring of uterine spiral arteries
that allow for the ﬂow of nutrients to the
placenta and ultimately to the fetus.114
Trophoblast cells play a central role in
this vascular remodeling process. Patho-
logic conditions that are associated with
trophoblast-directed uterine spiral artery
remodeling underlie some of the most
signiﬁcant and challenging obstetric dis-
eases.114-116 There are several research
strategies for gaining insight into the
process of hemochorial placentation and
for the identiﬁcation of potentially
vulnerable molecular mechanisms that
lead to disease. In this section, we address
the merits of animal models, especially
the rat, for placental research.
Placentation in the rat. The rat possesses
hemochorial placentation with deep
intrauterine trophoblast cell invasion
and trophoblast-directed uterine spiral
artery remodelling,117,118 which are fea-
tures shared with human placenta-
tion.114,119-121 Recognition of these
similarities spurred the establishment of
in vitro and in vivo research methods
using the rat as an animal model to
address mechanistic questions regarding
the development of the hemochorial
placenta and especially the role of inva-
sive trophoblast cells in the remodeling
of uterine spiral arteries. Rcho-1
trophoblast stem cells and blastocyst-
derived trophoblast stem cells are 2 rat
in vitro culture systems that have been
used extensively to investigate signaling
pathways and mechanisms that control
trophoblast cell differentiation.122,123Regulatory factors identiﬁed in vitro
have been tested experimentally with the
use of an assortment of in vivo research
strategies, which include transgenesis
to monitor the invasive trophoblast
lineage,124 spontaneous mutant rat
models that possess placental insufﬁ-
ciency118,125-128 and gain-of-function
and loss-of-function manipulations
with the use of trophoblast-speciﬁc
lentiviral gene delivery and genome
editing.129-132
A fundamental property of placenta-
tion is its plasticity, which is character-
ized by the acquisition of structural/
functional properties that permit adap-
tation to environmental challenges.
Mechanisms underlying these adaptive
processes are an important feature of
placentation and represent potential
therapeutic targets. Limiting oxygen de-
livery to the placentation site at devel-
opmentally deﬁned phases of gestation
effectively activates the acquisition of the
invasive trophoblast phenotype and
promotes uterine spiral artery remodel-
ing124,133 that are adaptive responses
conserved in primates.134,135 TheseJULY 2016 Amobservations illustrate the instructive
nature of oxygen delivery as signal-
driving decision-making within
trophoblast stem/progenitor cell pop-
ulations and ultimately affect hemo-
chorial placentation; however, it is
important to appreciate that failures in
adaptive responses to hypoxia can lead to
disruptions in placentation. Addition-
ally, hypoxia can also be a pathologic
response to a failed placenta resulting in
disease. Dissociating these potentially
confounding outcomes of hypoxia is
essential. Dissection of hypoxia-guided
pathways within trophoblast stem/pro-
genitor cell populations offers an op-
portunity to identify molecular events in
the placentation process that could be
manipulated to improve and enhance
placental development and prevent the
spiraling consequences of a failed
placenta.
Role of NK cells. Immune cells, especially
NK cells, are active contributors to
remodeling of uterine spiral arteries
during the establishment of pregnancy.
The involvement of NK cells in theerican Journal of Obstetrics& Gynecology S11
FIGURE 6
Natural killer cells and endovascular trophoblast cells contribute to
uterine spiral artery remodeling
A-D, Rats were treated on E4.5 and E9.5 with normal rabbit serum (control) or anti-asialo GM1
(natural killer cell depleted) and killed on E13.5. Double immunofluorescence staining for A, B,
ANK61 (natural killer cell marker) and ACTA (smooth muscle marker) and C, D, cytokeratin and
ACTA2. The asterisks demarcate blood vessels that possess interruptions (arrowheads) in the tunica
media (A, C); the asterisks identify blood vessels with intact tunica media (B). Scale bars¼ 0.25 mm.
NK, natural killer.
Reprinted with permission from Chakraborty et al.133
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been investigated effectively in the rat
(Figure 6). NK cells directly regulate
uterine spiral artery growth and pro-
gression towards the developing
placenta. These critical events impact
oxygen delivery to the placentation site
and trophoblast differentiation.133 Fail-
ures in NK cells result in attenuated
uterine spiral artery development, local
hypoxia at the placentation site, and
premature and exaggerated activation
of endovascular invasive trophoblast
cells that lead to extensive uterine spiral
artery remodeling. Thus, NK cells con-
trol oxygen delivery to the developing
placenta and regulate the timing
and extent of endovascular invasive
trophoblast cell differentiation and
trophoblast-directed uterine spiral ar-
tery remodeling. Evidence also existsS12 American Journal of Obstetrics& Gynecologysupporting a conserved role for uterine
NK-cell actions within the human
placentation site.136 Modulation of
uterine NK-cell behavior represents
another potential target for modulating
the placentation process.
Current opportunities. Animal models are
important tools to understand human
disease. Animal models provide the op-
portunity to study biologic phenomena
not easily studied in the human.
Although nomodel is ideal, each provides
useful insight relevant to the human
condition. The rat is a particularly
important experimental tool for investi-
gating regulatory processes that control
hemochorial placentation. Species dif-
ferences in placental organization and
gene expression patterns are evident, but
there are also underlying commonalitiesJULY 2016in structure, function, and especially
molecular mechanisms that regulate the
placentation process; when the time and
effort are taken to investigate these pro-
cesses, it has been demonstrated that
there is considerable merit for animal
models in placental research.120,137-140
Future opportunities.Maximal beneﬁts
for animal models in placental research
will be achievedwhen efforts are directed
to regulatory events and mechanisms
that are conserved in the human. The rat
has been used effectively to investigate
regulatory events that involve tropho-
blast cells, NK cells, and uterine spiral
arteries, a triad of key players in hemo-
chorial placentation.
A paradigm for investigating molec-
ular mechanisms that impact hemo-
chorial placentation with the use of
rodent trophoblast stem-cell models,
followed by the validation of the ob-
tained results in human placenta and
human trophoblast cell models, and
then proceeding to in vivo rodent
experimentation represents a powerful
research approach.131,141,142 Evaluation
of conservation generally is limited to
the use of primary or immortalized hu-
man trophoblast cell model systems and
expression analysis in human placental
tissues. A human trophoblast stem-cell
culture system functionally equivalent
to rodent trophoblast stem cells would
be optimal for studying the regulation of
differentiation, especially the identiﬁca-
tion of conserved processes. Some
progress has been made in the develop-
ment of this important experimental
in vitro tool.143 The recent availability of
genome editing strategies to generate
mutations in rodents should lead to the
establishment of new animal models for
in vivo testing of conserved molecular
mechanisms that control hemochorial
placentation. These in vivo approaches
should include targeting the activities of
speciﬁc trophoblast and immune cell
populations in order to identify molec-
ular pathways that could serve as sites for
therapeutic intervention.
Scientiﬁc gaps. The use of relevant and
appropriate animal models, including
rodents, to test hypotheses in vivo most
ajog.org Obstetrics Supplementimportantly extends placental research
beyond description, classiﬁcation,
in vitro analyses, and molecular pheno-
typing and permits a rational approach
for understanding the physiology of
placentation, the pathogenesis of
placental disease, and importantly the
identiﬁcation and testing of potential
drug targets for treating placental
disease.
Modeling placental function and
pregnancy physiology in mice
(James C. Cross, University of Calgary)
Background.Understanding the molec-
ular, cellular, and physiologic functions
of the placenta in humans is limited to
expression studies in normal and path-
ologic human pregnancies and some
in vitro systems. Because of this, animal
models remain critical for investigation
of the basic biology and assessment of
biomarkers and treatments of pregnancy
complications. The mouse has been a
powerful model for understanding ani-
mal biology in the last 25 years with the
advent of transgenic and knockout
technologies. Hundreds of different gene
knockouts in mice have given molecular
insights into the development and
function of the placenta. Many of these
genes have human homologues that are
expressed in the placenta.144,145 How-
ever, before zeroing in on genes and cells,
if mice are to be truly useful for under-
standing human pregnancy complica-
tions, it is critical ﬁrst to ask whether
mice and humans have similar physiol-
ogies of pregnancy. This is the starting
point for the use of mice to investigate
molecular mechanisms that give us
testable hypotheses to assess in human
studies.
Similar physiology of pregnancy in
humans and mice.Mice adapt to preg-
nancy with major changes in the
maternal cardiovascular, metabolic, and
immune systems. Similar to humans,
mice show increased cardiac output,
plasma volume, and a mid-gestation
drop in blood pressure.146,147 There are
also major changes in metabolism in
which the mother’s fat and muscle
become insulin resistant, requiring more
insulin to take up glucose, which helps toshunt glucose to the fetus.148 To combat
insulin resistance, an increase in
pancreatic b cells and insulin synthesis
occurs.149-151 Gestational diabetes mel-
litus (GDM) occurs if there is inadequate
b-cell compensation.152,153 The most
important change in the immune system
during pregnancy is the appearance of
large numbers of uterine NK cells in the
decidua,154 ﬁrst described in mice and
only later in humans. One difference
between mice and humans is that mice
are litter-bearing, whereas humans tend
to have singleton pregnancies; however,
what functional difference this has is not
clear, given the similarity of pregnancy
physiologic condition.
Trophoblast functions and pregnancy.
Most of the research on trophoblast cell
function in human pregnancy compli-
cations has focused on trophoblast cell
invasion and its association with spiral
artery remodeling. Cell ablation experi-
ments inmice showed that this is not just
an association and that trophoblast cell
association with spiral arteries is critical
for remodeling of those arteries,155
though uterine NK cells in the decidua
also play a role.156 Beyond just invasion
of spiral arteries, however, the human
placenta contains diverse extravillous
trophoblast subtypes,157 and mice have
diverse trophoblast cells in the junctional
zone that express complex patterns of
hormones.158
Several lines of evidence indicate that
the endocrine function of the placenta
modiﬁes metabolism in the mother that
is necessary to promote fetal growth.
Scanning through microarray data in
the public domain indicates that the
human placenta expresses >80 different
hormones.159 Although a few are
placenta-speciﬁc hormones arising from
duplication of the GH 2 gene most are
from canonical hormone genes that are
expressed in the placenta, presumably
because of evolution of placenta-speciﬁc
promoter and/or enhancers. The hor-
mones include known regulators of
metabolism, blood cell production
and reproduction. Placental prolactin-
related hormones can promote prolifer-
ation of pancreatic b cells and insulin
synthesis.160 Glucose transporter-relatedJULY 2016 Amhormones,161 progesterone,162 resis-
tin,163 and leptin164 can promote insulin
resistance. Paradoxically, the placenta
also produces adiponectin165 that pro-
motes insulin sensitivity. It is interesting
that, although these hormones are nor-
mally expressed by the pituitary (pro-
lactin, GH), ovary (progesterone), and
fat (the “adipokines”: resistin, leptin,
adiponectin), the human placenta is a
major source during pregnancy, and
production from the maternal tissues is
down-regulated.
The mouse placenta expresses
approximately 40 protein hormone
genes.166 As with humans, prolactin-
and GH-like hormones, progesterone,
resistin, leptin, and adiponectin are
elevated during pregnancy. However, the
evolution of the system is slightly
different because the prolactin gene, and
not the GH gene, is duplicated in mice to
produce 22 placenta-speciﬁc mem-
bers167 with prolactin- and GH-like ac-
tivities. In addition, the placenta is not
the only source of the other metabolic
hormones. Progesterone is produced by
the ovary throughout pregnancy in
response to stimulation by prolactin-like
hormones from the placenta.168 Resis-
tin,169 leptin,170 and adiponectin171 are
produced by fat during pregnancy in
mice. Prolactin receptor signaling can
regulate adipokine expression,172-174
which suggests the possibility that,
although the mouse placenta is not
the direct source of all metabolic hor-
mones, unlike humans, it may still
orchestrate the network. The best
evidence in mice that placental hor-
mones regulate fetal growth is that of
the pleckstrin homology-like domain,
family Amember 2 gene, which regulates
the fetal growth by inﬂuencing the
number of endocrine cells in the
placenta.175
Current opportunities.Despite the clear
evidence that placental hormones drive
fetal growth and regulate maternal
metabolism, it is curious that research
has not continued to understand their
roles in intrauterine growth restriction
(IUGR) and gestational diabetes mellitus
in humans. Placental hormones are
attractive targets from a diagnosticerican Journal of Obstetrics& Gynecology S13
FIGURE 7
Relationship of maternal
intervillous blood PO2 to fetal
umbilical venous PO2
Oxygen tension in the intervillous space of the
placenta is very low until the opening of the
spiral arteries to blood flow at approximately 10-
12 weeks of gestation. Light blue dots are in-
dividual data points that were obtained at 8-11
weeks gestational age. Medium blue dots are
data that were obtained from individual preg-
nancies at 11-16 weeks of gestation. Dark blue
dots are the mean of values that were obtained
in only a few women between 16-38 weeks of
gestation and have very wide confidence in-
tervals (>30 mm Hg). Red dots are umbilical
venous PO2. Note the tight relationship and
narrow diffusional gradient between intervillous
and fetal PO2 late in pregnancy. This Figure is a
composite of data obtained from various
references.182-185
Ilekis. Potential placental molecular therapeutic targets. Am J
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measured serially, and improvements in
multiplex immunoassays mean that
several hormones can be assessed at the
same time. Both hormone levels and
polymorphisms in the placenta GH-
related genes have been associated with
pregnancy complications in humans, 163
although the number of published
studies is limited and they have often
examined single hormones and not
made connections with anatomic
changes in the placenta.
Future opportunities. There is emerging
evidence from mouse studies that the
placental hormones are sensitive to
maternal nutrition and changes in their
levels likely reﬂect attempts to mitigate
the impact of poor nutrition on fetal
growth.176 Therefore, hormone levelsS14 American Journal of Obstetrics& Gynecologyshould have good predictive value in
reﬂecting both stress to the pregnancy
and the robustness of the placenta’s
ability to mitigate the impact on the
fetus. In addition to diagnostic value, it is
easy to imagine therapeutic strategies in
which hormone supplementation or
blockade is used to treat pregnancy
complications.
Scientiﬁc gaps. The complexity of the
hormone network at play during preg-
nancy, both the number of hormones
and the systems of feedback and adap-
tation, will require the use of animal
models, particularly knockout and
transgenic mice, to understand them.
With the ability to study mouse physio-
logic condition, it is clear that, although
a mouse is not a human, we certainly can
learn from them.
Potential drug targets of important
placental pathways in relation to
pregnancy disorders
Placental hypoxia as a molecular target
(Stacy Zamudio, Hackensack
University Medical Center)
Background.Hypoxia is a pathologic
condition in which there is insufﬁcient
oxygen to maintain normal physiologic
processes. However “hypoxia” is often
used imprecisely in the literature, inter-
changeably with some of its causes,
for example: hypoxemia-reduced partial
pressure of oxygen (PO2), anemia
(insufﬁcient hemoglobin or hemoglo-
binopathies that alter oxygen binding/
release), or reduced environmental
oxygen availability (as in high-altitude
animals dwelling in burrows, diving
mammals). Hypoxia is usually assumed
to be present in any 1 of these conditions.
For example, a reduction in blood ﬂow
to a speciﬁc organ or tissue, whether
acute or chronic, often is assumed to be a
hypoxic insult. However, hematologic
adaptations can compensate for lower
blood ﬂow,177 and the volume and speed
with which blood travels, as well as
diffusional distances, affect tissue oxygen
delivery.178-182 Thus, in the absence of
direct measures of oxygenation in the
tissue, cell, or organ of interest, it is
difﬁcult to tell whether hypoxia is
present.JULY 2016Oxygen levels in the human placenta and
fetus.Normal oxygen levels within the
intervillous space of the placenta are
low early in gestation (approximately
20 mm Hg), can rise to as high as
80 mm Hg in the early second trimester,
and then decline progressively towards
term (Figure 7).183-186 Fetal umbilical
venous PO2 follows a similar pattern,
perhaps reaching as high as 40-50mmHg
in the second trimester, but also
declining progressively towards term to
an average ofw28 mmHg (<4% O2) at
term. Rising hemoglobin maintains
oxygen content. With normal values as
low as these, even small changes in fetal
PO2 can make a difference. Average
umbilical venous PO2 differs by only
3 mmHg in babies at >97% percentile
versus those at <3rd centile.187 Despite
difﬁculty in quantifying magnitude and
intensity of hypoxia,much less being able
to detect its onset, the bulk of evidence
has led to general acceptance that fetal
growth diseases often are associated with
placental hypoxia, speciﬁcally early-
onset preeclampsia, most nongenetic/
syndromic IUGR, preeclampsia with
IUGR, and some diabetes/GDM with
large for gestational age neonates.188-196
Figure 7 shows that what might be
considered abnormally low O2 levels in
the placenta will vary not only by gesta-
tional age, but also with location within
the placenta. The third-trimester
placenta is exposed to PO2s that can
range from <20 mm Hg when the
deoxygenated blood from the umbilical
artery ﬂows back into the placenta to
>80 mm Hg when the maternal arterial
blood ﬁrst enters the intervillous space.
This equates to 1-10% ambient O2 for
in vitro experimentation. Such data have
given rise to a convention in which 5-8%
O2 is used tomimic normoxic conditions
in the third trimester and <3% for
hypoxia.
Placenta hypoxia cannot be diagnosed
unambiguously because of the inherent
limitations of human experimentation
and the inaccessibility of the placenta
and fetus in vivo. Proxies are used
instead. For example, reduction in blood
ﬂow severe enough to deprive tissues of
oxygen and glucose sufﬁcient for meta-
bolic needs is assumed to be present
ajog.org Obstetrics Supplementwhen elevated maternal/fetal Doppler
indices reﬂect increased impedance.
Elevated erythropoietin levels in
mothers and babies, nucleated red blood
cells in neonates, increased placental
expression of hypoxia-inducible-factor
(HIF), and its target gene products
have all been used to demonstrate
that placental hypoxia is present in
fetal growth diseases.192,197-209 Thus,
placental hypoxia is a target for thera-
peutic intervention, and unlike some of
the topics discussed at this workshop,
there have already been a number of
clinical trials designed to ameliorate or
prevent presumed consequences of
hypoxia such as inﬂammation210 and
oxidative stress.211-214
Chicken and egg, cause and effect.Of
critical importance is distinguishing be-
tween hypoxia per se and the hypoxia
response. The hypoxia response is evi-
dence that hypoxia is or has been present
(eg, up-regulation of HIF and HIF-
regulated genes, higher fetal hemoglo-
bin concentrations). The strength and
magnitude of the response may reﬂect
the intensity of the insult, but it is also
often adaptive in that it enables mecha-
nisms that increase the delivery of oxy-
gen to the fetus (as in metabolic
reprogramming or the development of
decreased vascular syncytial membrane
thickness). On the other hand, we must
be mindful of the possibility that failure
of an appropriate hypoxia response may
itself be part of the pathologic condition.
There is evidence of HIF dysregulation
and consequent over-expression without
adaptation in the more severe forms of
preeclampsia.207,208,215 In contrast, in
some severe, early-onset IUGR, there
often appears to be a lack of HIF-
mediated responses, when all evidence
suggests such response is needed.216-218
Studies at high altitude have revealed
the importance of being able to distin-
guish between adaptive hypoxia
response and pathologic condition, as
well as the subtlety with which O2 ten-
sion can exert an effect. Maternal partial
pressure of O2 in arterial blood (PaO2)
falls considerably at 2700-m elevation;
because of the sigmoid shape of the
O2 dissociation curve, PaO2 fallsprecipitously at >3000 m. Even in
pregnancies with entirely normal out-
comes, physiologically lowered maternal
PaO2 results in a progressive slowing of
the third-trimester fetal growth trajec-
tory.219,220 This is despite signiﬁcant
placental adaptation both structurally
(increased angiogenesis, decreased
vascular syncytial membrane thickness)
and metabolically.221-226 Altitude studies
in vivo showed that the human placenta
that is subjected to hypoxic stress engages
in a highly conserved process most
obviously seen in solid tumors.227-230
Metabolic reprogramming is a revers-
ible form of hypometabolism inwhich an
effective, largely mitochondrial-driven
switch from oxidative phosphorylation
to aerobic (ie, glycolytic) glucose con-
sumption by the trophoblast results in
increased cellular oxygen availability,
which is then available for diffusion to
the fetus.224,225 In essence, the mecha-
nism “spares” oxygen for the fetus, but at
the same time reduces fetal access to
glucose. This slows fetal growth but en-
sures that the fetus does not outgrow its
supply line. Even when placental meta-
bolic programming is active, a fetus with
greater umbilical venous O2 tension
consumes more O2.
How might hypoxia be ameliorated?
Therapeutic strategies must necessarily
depend on what is the pathologic barrier
to normal placental oxygen diffusion.
Four targets will be considered here:
blood O2 content, uteroplacental blood
ﬂow, placental structure (angiogenesis),
and hypoxia-induced metabolic
reprogramming.
Raise arterial O2 content (CaO2) or
PaO2. In women who are anemic, the
obvious treatment would be increasing
maternal red cell mass and thereby
increasing CaO2. This is harder than it
sounds because women have less of a
response to erythropoietin than do
men,231 and the condition of up to 25% of
pregnant women who are treated with
erythropoietin does not respond.232 At
high altitude CaO2 is increased by raising
hemoglobin concentration. This preserves
maternal and fetal oxygen delivery176,233
despite an approximate 20% reductionJULY 2016 Amin uterine artery blood ﬂow in mothers
and an even greater decrement in fetal
umbilical venous blood ﬂow. Packed red
blood cell transfusion might work for
anemic mothers, but it is unlikely to be of
value where the barrier to O2 diffusion is
due to placental structural defects such as
the failed tertiary villous vascular devel-
opment (branching angiogenesis and
elongation/dilation of terminal capillary
loops) seen in idiopathic IUGR.Moreover,
there is a balance that must be maintained
between blood viscosity and O2 carrying
capacity (eg, the optimal hematocrit level
for preservation of O2 delivery in the brain
microcirculation is 15-40%).234 One
obvious method for increasing PaO2 is O2
supplementation. Sadly, a 2003 Cochrane
review found that, of 10 trials of O2 ther-
apy, only 3 were adequate for inclusion in
a metaanalysis. O2 compared with no O2
was given to mothers for improvement of
fetal growth. Rereview in 2009 changed
none of the Cochrane conclusions because
no additional trials were undertaken.235
The trials were poorly designed and
involved <100 women. However, 24-hr
supplemental O2 led to a decrease in the
perinatal mortality rate. The studies were
confounded in that the O2-treated group
was of greater gestational age at initiation
of treatment. Concerns over possible
response to “hyperoxia” such as the gen-
eration of free radicals, the inhibition of
potentially adaptive responses ongoing in
fetus and placenta have been raised as
objections to O2 therapy.
Blood ﬂow. Deﬁcits in uteroplacental or
fetal blood ﬂow are associated strongly
with preeclampsia and IUGR as evi-
denced by Doppler ultrasound measures
of impedance to blood ﬂow in the uter-
ine arteries and within the fetus. The
studies in which blood ﬂow in human
pregnancy complications has been
measured quantitatively or semi-
quantitatively support this.236 Absent or
reversed end diastolic blood ﬂow veloc-
ity in the umbilical arteries is a grave sign
and usually leads to emergent de-
livery.237 Elevated Doppler resistance
indices in the maternal uterine arteries
indicates that there is downstream
impedance to blood ﬂow. This is
accompanied by morphologic evidenceerican Journal of Obstetrics& Gynecology S15
Supplement Obstetrics ajog.orgof placental structural problems such as
a reduction in small arteries within the
tertiary stem villi,238 thickening of the
basal lamina, and erythrocyte congestion
in tertiary villous capillaries.239,240 As
with CaO2 or PaO2, how onemight target
blood ﬂow depends on what is the un-
derlying problem. Most of the blood
entering the intervillous space is carried
by the maternal uterine arteries. The
uterine arteries therefore are critical to
pregnancy success and a potential target.
In normal pregnancy, eccentric remod-
eling of the uterine arteries leads to
doubling of uterine artery diameter by
20 weeks of pregnancy and a further,
smaller increase, likely because of shear
stress, in the late third trimester.241
Eccentric remodeling is characterized
by changes in the composition of the
vessel wall that permits greater distensi-
bility. In addition, there is inhibition of
the myogenic response (the rise in vessel
tone with increasing pressure).242-244
In human and multiple experimental
animal models, endothelium-dependent
vasodilator response is increased mark-
edly in the uterine circulation during
pregnancy. In rodent models, depending
on what branch of the uterine artery
is investigated, nitric oxide contributes
30-80%, and endothelium-derived
hyperpolarizing effectors contribute
20-70% of the endothelium-dependent
vasodilator response of the pregnant
uterine arteries.245,246
Placental structure (eg, angiogenesis). In
idiopathic IUGR, the placenta frequently
has a dearth of branching angiogenesis
and poorly developed tertiary capillary
development, leading to reduced O2
diffusion capacity.178,216 Structural
placental defects in preeclampsia are less
clear. An excess of ﬁbrinoid deposition
leading to, or as a result of, villous death
has been attributed to excess oxidative
stress or inﬂammation. In women with
preeclampsia, in general, placentas are
smaller (reduced weight and volume),
and the volume of functional tissue (pa-
renchyma) and villous surface area (area
of nutrient and gas exchange) are
reduced. 247 However, unlike IUGR, they
also have an increase in the fetal capillary
volumes and density (indicative of aS16 American Journal of Obstetrics& Gynecologyhypoxia response). Late onset pre-
eclampsia (without fetal compromise)
shows no such changes and cannot be
statistically differentiated from normal
placentas.248 The interplay of many
angiogenic growth factors and of several
critical cell types (pericytes, endothelium,
trophoblasts) is involved in the normal
vasculogenesis of the placenta.223,249
Placental metabolic reprogramming. In
cancer biology, several recent unique
insights are relevant to the placenta and
consideration of molecular pathways
that might be amenable to therapeutic
intervention. Cancer cells have dysregu-
lated, Warburg-like glucose metabolism.
Energy production is abnormally
dependent on aerobic glycolysis; there is
increased fatty acid synthesis and
increased rates of glutamine meta-
bolism.250 In fact the term glutamine
addicted is now applied to many can-
cers.251 In cancer biology “glutamine
addicted” refers to an extension of
metabolic reprogramming in which
glutamine is required for essential amino
acid uptake to maintain activation of
mTOR. In many, if not all cancer cells,
glutamine is also the primary mito-
chondrial substrate. These metabolic
changes are linked to therapeutic resis-
tance in cancer treatment; hence, stra-
tegies are being developed to target this
altered cancer metabolism in conjunc-
tion with older treatments that were
designed to inhibit angiogenesis or
otherwise shrink the tumor.252,253 We
have demonstrated the same, evolu-
tionarily conserved mechanism of
metabolic reprogramming in the hyp-
oxic placenta that is associated with
stably elevated HIF-1alpha levels,
which initiates metabolic reprogram-
ming.205,224,225 However, in contrast to
cancer, the objective of a therapy that
targets metabolic reprogramming in
the placenta would be to sustain the
response, which leads to increased
intracellular oxygen levels and hence
more oxygen for diffusion to the fetus.
Current opportunities. There is wide-
spread acceptance that placental hypoxia,
acknowledging the already low
O2 environment that is normal, isJULY 2016associated with pregnancy diseases.
However, before a placental molecular
intervention is attempted, there should be
a greater effort to examine relatively
noninvasive means of improving
oxygenation in the placenta. These should
include deﬁnitive studies of maternal O2
supplementation, dietary strategies
designed to increase maternal substrates
for nitric oxide, and other obviously more
benign strategies that target maternal
physiologic condition rather than
placental function.
Methods that might be used to pro-
vide additional means of carrying oxy-
gen in the circulation (eg, oxygen-ﬁlled
microbubbles) are under investiga-
tion.254-257 Moreover, the opportunity
exists currently to further test the effects
of supplemental O2; more modern
standards of clinical trials such as
establishing dose/response, effects of
treatment duration, minimum dosing
necessary surely should be attempted
as a simple, yet potentially, effective
intervention.
Beyond this are the effectors that are
responsible for altering vascular tone that
could be molecular targets, including
nitric oxide, by stimulating release via a
number of means that include the
administration of VEGF, PlGF, relaxin,
or stimulation of the reticular-activating
system, hemoxygenaseecarbon monox-
ide, large conductance Ca2þ- activated
potassium (Kþ) channels, and in-
creased dietary intact of arginine or
citrulline.258-260 For endothelium-derived
hyperpolarization, potential effectors
include Kþ C-type natriuretic peptide,
arachidonic acid derivatives, epox-
yeicosatrienoic acids and hydrogen
peroxide.
Three approaches have been or
currently are being investigated to in-
crease blood ﬂow. The least invasive of
these involves dietary arginine (or
citrulline) supplementation, in theory,
to increase substrate for nitric oxide
production. A number of small trials led
to 1 randomized controlled clinical
trial.261 High-risk women (with a history
of preeclampsia in the previous preg-
nancy) had less than one-half the rate
of preeclampsia as women receiving
placebo. However, another trial in
ajog.org Obstetrics Supplementwomen already diagnosed with pre-
eclampsia and treated acutely, rather
than throughout pregnancy, showed no
beneﬁt.262 International recruitment for
a trial is ongoing for the treatment of
early-onset IUGR.263 This 6-year study
was based on several small studies
that showed that low-dose sildenaﬁl
improved fetal growth and neonatal
survival.264 Another trial that is ongoing
and led by Dr Anna David in the United
Kingdom targets women with even
earlier IUGR, women whose IUGR is so
severe that the fetus normally would die
before viability.265 Treatment consists of
uterine artery catheterization and injec-
tion of adenovirally delivered VEGF-D.
Proof of concept studies in sheep
demonstrated that this treatment im-
proves uterine artery blood ﬂow for
approximately1 month.266
Future opportunities.With respect to
angiogenesis, cancer therapies, especially
for solid tumors, provide some clues.
These therapies target the inhibition of
angiogenesis, although, in the placenta,
one might wish to stimulate organ-
speciﬁc angiogenesis. Effectors in this
molecular pathway provide a variety of
targets. Vascular endothelial-cadherin
and matrix metalloproteinases, for
example, loosen gap junctions in
the endothelium, which is required for
tip-cell formation, a prerequisite to
branching angiogenesis. However, tip
cell formation also requires coordinated
activity by VEGFR-2, various ligands for
Notch-1 receptor (such as Delta-like
ligand and jagged 1), neuropilin 1,
integrins, HIF-1a, and angiogenic
growth factors such as VEGF, ﬁbroblast
growth factors, angiopoietins.
Metabolic reprogramming is HIF-
dependent, and, as indicated earlier,
HIF may be dysregulated in some
placental diseases. Targets other than
HIF that could be manipulated to sus-
tain the metabolic response to hypoxia
might include a variety of enzymes:
hexokinase, pyruvate kinase M2, lactate
dehydrogenase A, pyruvate dehydroge-
nase kinase, fatty acid synthase, and
glutaminase.
Inhibition of HIF-1a or its gene
products has been a primary focus inthe development of cancer drugs.
There are >400 drugs that speciﬁcally
target the HIF pathway, most of them
inhibitory. Many of them also target
speciﬁc, cancer-related mutations that
are related to the HIF pathway; hence, a
reverse-engineering approach could be
applied to existing drugs to see whether
they would be beneﬁcial, as has been
done in human immunodeﬁciency vi-
rus.267,268 A placental strategy might
consist of controlled up-regulation of
HIF-1a, because it is known to be
elevated stably in hypoxic placentae
and likely contributes to the increased
angiogenesis that is a favorable adap-
tation when placental hypoxia is pre-
sent but not associated with a
disease.220
Scientiﬁc gaps. For further advances in
molecular targeting, greater information
is required in a number of areas. For
example, although there is a large
quantity of data on the role and effects of
vasodilators, the receptors for these
agents are understood poorly. Although
a targeted increase in receptors for va-
sodilators would be a possible thera-
peutic strategy, we clearly require more
knowledge of the broader effects of re-
ceptor modulation.
Similarly for the angiogenic growth
factors, what are the consequences if
some, but not other angiogenic growth
factors, are targeted in the placenta.
What might be the response to modu-
lating the angiogenic growth factor re-
ceptors rather than the growth factors
themselves? Might it be possible to
devise tissue and/or cell type selective
modulation that would bypass the
problems of the less-controlled distri-
bution of the ligands? Placental
vascular pericytes have been suggested
as a hematopoietic stem cell or
mesenchymal stem cell. They are
involved intimately in vessel stability
and angiogenesis.269-271 Pericytes can
be detached from their vascular niche
by angiopoietin-2, which would in-
crease the stimulus for branching
angiogenesis. Again we lack more
knowledge to determine whether these
supporting characters may be the key to
successful vascular therapies.JULY 2016 AmIs fetal growth a feasible target for
placental intervention? (Nicholas P.
Illsley, Hackensack University
Medical Center)
Background. Alterations in fetal nutrient
concentrations because of changes in
placental transport and/or metabolism
are associated with a variety of fetal
growth diseases. Deﬁcits in oxygen are
associated with hypoxia, preeclampsia,
and IUGR. Deﬁcits in glucose and/or
amino acids are associated with IUGR,
and an excess of glucose is associated
with macrosomia, obesity, and diabetes
mellitus. Alterations in placental
nutrient transporters are associated with
a variety of fetal growth diseases; the
glucose transporter 1 in hypoxia and
diabetes mellitus272,273 and amino acid
transporters in IUGR and diabetes mel-
litus.274,275 The simplest possibility in
these circumstances would be to reverse
these deleterious changes by manipula-
tion of maternal substrate levels. There
are situations in which action to reba-
lance abnormal nutrient concentrations
is capable of correcting growth prob-
lems: the restoration of normal maternal
glycemic status to prevent macrosomia
being an example. Overall, however, the
record with regard to maternal nutrient
supplementation is 1 of minimal effect
combined with potentially serious side-
effects.276
Another set of important questions
revolves around timing. Is there a win-
dow during which intervention is
possible, and perhaps more importantly,
how do we know when intervention is
necessary? In answer to the former,
intervention is clearly preferable before
structural and biochemical changes
make the growth restriction process
difﬁcult to reverse, leading to the latter
question: how do we detect the initial
stages of growth restriction? The best
indicator we have currently that fetal
growth is deviating from normal is the
fetal growth trajectory derived from
serial ultrasound measurements. Given
that this requires multiple measure-
ments over weeks of gestation, by the
time we can verify growth restriction, the
fetus (and placenta) are already well
advanced through pathologic changes in
growth. This crude indicator signals aerican Journal of Obstetrics& Gynecology S17
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and, at best, will allow for stabilization of
growth at a much lower percentile. It is
clear that, without a means to detect
the early stages of the processes that
contribute to growth restriction, inter-
vention will lag well behind. Our own
research into placental metabolic pro-
cesses has shown that the early stages
of growth reduction involve a switch
away from oxidative metabolism toward
an increased level of glycolytic meta-
bolism (placental metabolic reprogram-
ming).277 As a potential early indicator
of growth problems, the initiation of
placentalmetabolic reprogrammingmay
provide the crucial biomarkers needed to
detect the ﬁrst stages of an altered
growth trajectory.
Current opportunities. Assuming that
combined biochemical/imaging methods
will eventually detect at-risk pregnancies,
what might we focus on as placental
targets for intervention? Is it possible to
see nutrient transporters as possible
molecular targets? The ones that concern
us here are those that transport the
essential, higher volume nutrients,
including glucose, amino acids and fatty
acids. Because the high volume glucose
transporters (ie, GLUT1 and GLUT3)
demonstrate unique polarized distribu-
tions between the maternal-facing
microvillous and fetal-facing basal sur-
faces,278,279 altering the balance of glucose
transporters within the syncytiotropho-
blast raises with it the question of the
selective polarized targeting that is needed
to achieve increased transport. The
polarized targeting question arises also
for amino acid transporters when the
asymmetric distribution acts to move
sufﬁcient quantities and types of amino
acid against their gradient into the
fetus.280 In the absence of targeting in-
formation for these transporters, we need
to be assured that interventions will
provide the appropriate distribution be-
tween microvillous and basal faces
necessary to increase ﬂux. Moreover, the
effects of increased transporter density,
although possibly increasing trans-
placental ﬂuxes, will also pose other
problems. In the case of glucose, this is
likely to generate increased glycolyticS18 American Journal of Obstetrics& Gynecologymetabolism and subsequent lactic
acidosis, as observed in glucose supple-
mentation interventions. In the case of
amino acids, the interconnected nature of
their transport and the broad substrate
speciﬁcity of amino acid transporters
suggest that alterations to an individual
transporter will have signiﬁcant and
hard-to-predict ramiﬁcations for the
transport of other amino acids and for
placental amino acid metabolism. Simi-
larly, it is difﬁcult to predict what the ef-
fect of altering the expression of placental
lipases, fatty acid transport, or fatty acid
binding proteins might be on processes
such as oxidative metabolism and the
transport of other nutrients. The essen-
tial, high-volume nutrients have a wide
range of metabolic fates, and they or their
metabolites play crucial roles in regu-
lating key metabolic pathways. Not sur-
prisingly therefore, changes in the
expression of individual nutrient trans-
porters are likely to be associated with
unwanted changes in placental and/or
fetal metabolism. The uncertainty
engendered by the alteration of individual
transporters makes them problematic
candidate molecular targets.
An alternative approach to targeting
individual transport or metabolic pro-
cesses is the generation of alterations in a
manner that combines multiple meta-
bolic and/or transport targets. In this
way, the transport and metabolic pro-
cesses that involve speciﬁc substrates are
modulated in an integrated fashion. We
already have detailed information on
many of these integrated pathways. They
form the traditional endocrine or growth
factor pathways that mediate regulation
of cellular function by extracellular fac-
tors. We know for example that insulin-
like growth factor I (IGF-1) regulates the
expression of placental glucose and
amino acid transporters281,282 and that it
is associated positively with fetal and
placental growth.283,284 Judicious
adjustment of the placental IGF-1
pathway might allow for an integrated
regulation of growth processes. Recent
research has shown that adenoviral-
mediated delivery of IGF-1 to the
placenta appears to stimulate glucose
and amino acid transporter expression
in vivo and to correct placentalJULY 2016insufﬁciency.285,286 Similar types of
growth factor-mediated regulation
might be possible via the signaling
pathways stimulated by IGF-2 or
placental GH. Perhaps the molecular
targets for these pathways might be
restricted to selected cell types by
altering receptor levels rather than
altering the concentration of the growth
factors themselves.
Future opportunities. Although the effec-
tors described earlier may be able to
stimulate integrated pathways for the
promotion of fetoplacental growth, the
signaling pathways that are activated in
this way may be too numerous or too
broadly based to avoid other less desir-
able effects. Growth factor signaling
pathways frequently have many trans-
duction pathways that branch off below
the growth factor receptor. Another
alternative is the targeting ofmetabolic or
signaling subnetworks that control mul-
tiple components but do not extend to all
of the endpoints for a signaling pathway.
For examplemTOR is a serine kinase that
is the focus of a signaling pathway that
forms a nexus for multiple nutritional
and metabolic signals. MTOR affects
growth by modulating protein synthesis,
lipid synthesis, and energy metabolism,
primarily through phosphorylation of
the 4E-binding proteins that in turn have
marked effects on the production of the
proteins that control messenger RNA
(mRNA) translation.287 In the placenta,
in addition to effects on protein synthe-
sis, mTOR appears also to modulate
amino acid transporters by regulating the
membrane trafﬁcking of transporter
protein.289 There is good evidence to
suggest that mTOR activity is propor-
tional to maternal body mass in-
dex288,289; however, in IUGR, syncytial
mTOR, while displaying increased
expression, shows decreased activ-
ity.288,290 This suggests that the mTOR
pathway may be a good potential regu-
latory point for growth-related inter-
vention. Is it possible, for example, to
target the mTOR system directly, below
the broadly regulatory phosphatidyli-
nositol-3-kinase/protein kinase B stage
(Figure 8)? Activation via agents, such as
the small experimental drugs MHY
FIGURE 8
Metabolic mechanistic target of rapamycin intervention points
Potential intervention points (open arrows) for modulation of placental metabolism. These range from
extracellular endocrine regulation by insulin-like growth factor I through effects on mechanistic target
of rapamycin by activators such as 3BDO (3-benzyl-5-[(2-nitrophenoxy) methyl]-dihydrofuran-2[3H]-
one) or MHY 1485 (4,6-dimorpholino-N-[4-nitrophenyl]-1,3,5-triazin-2-amine) to points in the
metabolic subsystems regulated by mechanistic target of rapamycin. The question marks indicate
possible stages in the mTOR pathway that can be targeted.
IGF-I, insulin-like growth factor I; mTOR, mechanistic target of rapamycin.
Ilekis. Potential placental molecular therapeutic targets. Am J Obstet Gynecol 2016.
ajog.org Obstetrics Supplement1485291 or 3BDO,292 might conﬁne the
effects to a smaller set of endpoints than
the use of IGF-1. Will it be possible to
selectively target functions below the
level of mTOR, for example modulating
amino acid transporter expression via
changes in microtubule organization?293
Another possibility is suggested by the
inhibitory actions of metformin on
oxidative metabolism.294 Might it be
possible to initiate or extend placental
metabolic reprogramming effects
through artiﬁcial stimulation of
placental oxygen sparing and consequent
increased glycolytic metabolism?295 Ac-
tion via subsystems may avoid the lateral
signaling effects of classic growth factors
while providing for conﬁned, but inte-
grated, stimulation. This will require
detailed knowledge of the subsystems
that are involved and raises the question
of targeting and speciﬁcity.
Scientiﬁc gaps. Like substrate supple-
mentation, alteration of an individual
transporter appears likely to distort the
transport and metabolism of other sub-
strates and metabolites. Modulation of
systems that integrate multiple aspects
related to nutrient transfer, whether by
endocrine or intracellular subsystem
approaches, is likely to be more suc-
cessful. This requires not only detailed
knowledge of the pathways involved but
also understanding of the lateral or
related pathways that may be affected to
prevent generation of off-target effects.
Whether stimulation via a growth fac-
tor pathway or an intracellular subsystem,
a prerequisite is to restrict the site of ac-
tion to the trophoblast. Renewed atten-
tion is required to the delivery vehicles for
agents of interest. Some of the vehicles for
these actions are under development.
Viral or homing-peptide directed nano-
particles carrying directly active agents or
vectors with trophoblast-speciﬁc pro-
moters may provide the means to over-
come questions of targeting and
speciﬁcity. But just as importantly, timing
is everything! Unless it is possible to
detect changes in nutrient transport or
growth early enough to intervene, modi-
ﬁcation of nutrient transport may exac-
erbate rather than resolve problems.
Research to determine the onset ofpathologic events and the means to
monitor growth and the ameliorative ef-
fects of targeted interventions is an aspect
of this process that is just as important as
the intervention itself.
Targeting oxidative /nitrative stress
and mitochondrial dysfunction in
placenta to relieve adverse pregnancy
outcomes (Leslie Myatt, University of
Texas Health Science Center San
Antonio)
Background. It has long been recognized
that pregnancy is a state of oxidativeJULY 2016 Amstress and that this is further increased
in ﬁrst, second, and third trimesters
in pregnancies that result in adverse
outcomes such as preeclampsia and
diabetes mellitus,296 preterm birth,297
stillbirth,298 and in those pregnancies
complicated by maternal obesity.299
However, a cause-and-effect relation-
ship between increased oxidative stress
and adverse pregnancy outcomes still
remains to be proved deﬁnitively.
Oxidative stress is deﬁned as an imbal-
ance between the production of reac-
tive oxygen species (ROS), includingerican Journal of Obstetrics& Gynecology S19
FIGURE 9
Generation of oxidative and
nitrative stress
Superoxide generated frommolecular oxygen by
membrane bound (myeloid differentiation pri-
mary response gene 88 oxidase) or cytosolic
(xanthine oxidase) enzymes or the mitochondrial
electron transport chain normally can be effec-
tively dismutated to hydrogen peroxide by su-
peroxide dismutase. Increased superoxide will
attack targets, which leads to oxidative stress.
With increasing generation of nitric oxide, nitric
oxide out competes superoxide dismutase for
superoxide and interacts to produce the more
powerful prooxidant peroxynitrite. Peroxynitrite
nitrates proteins at tyrosine residues and cova-
lently modifies function usually in a negative
manner. Superoxide dismutase is inactivated
when nitrated by prooxidant peroxynitrite, hence
leading to a negative feedback loop that leads to
oxidative and nitrative stress.
NO, nitric oxide; ONOOe, prooxidant peroxynitrite; SOD, super-
oxide dismutase.
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peroxide, and the ability of various
antioxidant mechanisms to scavenge
them. Further, ROS can also interact
with reactive nitrogen species such as
nitric oxide to produce the powerful
prooxidant peroxynitrite, which, in turn,
can nitrate tyrosine residues in proteins,
such as superoxide dismutase300 (SOD;
Figure 9), causing nitrative stress, which
affects protein function, usually in a
negative manner.301 Not all reactive
oxygen and nitrogen species are equal in
potency, that being determined by their
cellular diffusion distance, deﬁned as
the distance moved in aqueous solution
in 1 half-life. Hence, hydroxyl anion has
a diffusion distance of only 5 angstroms,
superoxide 0.4 mm, peroxynitrite 5 mmS20 American Journal of Obstetrics& Gynecologyand nitric oxide 100 mm.302 Therefore, in
the placenta, the sites of action (intra- vs
extra- or transcellular) depends on
intracellular and cellular site of synthesis
in relation to placental structure such as
trophoblast thickness (5mm), stem
villous diameter (500-1500mm), and the
presence of antioxidant molecules to
scavenge them.303
Role of mitochondria. The major sources
of ROS are the mitochondrial electron
transport chain but also plasma mem-
brane enzymes, such as the nicotinamide
adenine dinucleotide phosphate oxi-
dases, cytosolic enzymes (including
xanthine oxidase, ﬂavin enzymes, and
cytochrome p450s), lipoxygenases, and
cyclooxygenases.295 Although widely
acknowledged for their pathologic ef-
fects that include covalent modiﬁcation
of proteins, lipids, and DNA, ROSs also
function as physiologic effectors, regu-
lating redox sensitive genes and pro-
teins.304 There are many methods
available to measure ROS. Because of
their ephemeral nature, direct measure-
ment of ROS is difﬁcult; therefore,
measurement of effects that include lipid
peroxidation, covalent modiﬁcation of
proteins, DNA damage and repair, levels
and activity of antioxidant molecules
and enzymes, and enzymes generating
ROS are used. There is no gold standard
measure of oxidative stress; rather one
should chose a measure related to the
area of interest.305
Mitochondria have many roles in
cellular function in addition to energy
production, which includes apoptosis,
steroid synthesis, calcium homeostasis,
and amino acid transport. Changes in
mitochondrial activity can be induced by
environmental factors such as nutrition,
hypoxia, aging, and obesity that impact
cellular survival and that are associated
with adverse pregnancy outcome. Mito-
chondria are the major source of ROS
under physiologic conditions because of
the release of high-energy electrons from
complexes I and III of the electron
transport chain; these electrons reduce
molecular O2 to superoxide, which
normally is scavenged by the mito-
chondrial SOD isoform, mitochondrial
antioxidant manganese SOD. However,JULY 2016mitochondrial function itself can be
compromised by severe and/or pro-
longed oxidative stress via damage to
mitochondrial DNA, proteins, and
lipids. We recently have shown that
maternal adiposity leads to increased
oxidative stress in the placenta and that
this is associated with decreased
trophoblast mitochondrial respiration
measured in vitro using a Seahorse
extracellular ﬂux analyzer (Seahorse
Bioscience, Copenhagen, Denmark).306
This dysfunction is further evidenced
by decreased mitochondria number,
expression of complexes I-V of the elec-
tronic transport chain, and decreased
placental adenosine triphosphate gener-
ation. In addition, these trophoblasts
appear metabolically inﬂexible because
they cannot switch to alternative energy
sources when placed on galactose to
prevent glycolysis.305
Current opportunities. Subsequent to
acquiring knowledge of increased
oxidative stress in pregnancies with
adverse outcomes, there have been many
trials of antioxidant therapy to try and
prevent these outcomes.307 All have
failed, which is an outcome variously
attributed to choice of antioxidant, time
and duration of treatment, heterogeneity
of patients studied, the fact that oxidative
stress may indeed not be part of the
pathophysiologic evidence, or the need
for targeted rather than global therapy.
This begs the question: what are the tar-
gets at the tissue and cellular levels?
Should antioxidants that are targeted to
placenta by use of nanoparticles or
liposomes be used rather than global
treatment? Cellular targets could include
antioxidant enzymes such as SOD,
glutathione peroxidase, thioredoxin
reductase and catalase, the enzymes that
synthesize ROS such as xanthine oxidase
and nicotinamide adenine dinucleotide
phosphate oxidases, extracellular anti-
oxidants (transferrin, ceruloplasmin,
uric acid, and bilirubin), intracellular
reducing elements (glutathione, coen-
zyme Q10, and cytochrome c oxidase)
and nutrients and supplements such as
vitamins C and E andmelatonin. Because
mitochondria are the major source of
antioxidants, there has been growing
FIGURE 10
Putative mechanism for the
involvement of inflammation-
mediated placental dysfunction
in fetal programming
The adverse inflammatory maternal environ-
ments of gestational diabetes mellitus, pre-
eclampsia, or obesity can generate increased
oxidative/nitrative stress and cause mitochon-
drial dysfunction in the placenta in a sexually
dimorphic manner. This disrupts placental
function and in turn may lead to alterations in
placental-mediated regulation of maternal
metabolism and fetal growth and differentiation
and hence result in fetal programming.
GDM, gestational diabetes mellitus.
Ilekis. Potential placental molecular therapeutic targets. Am J
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antioxidants by compounds such as the
mitochondria-targeted antioxidant drug,
MitoQ, where coenzyme Q10 is linked to
a lipophilic cation to allow adsorption
through the inner mitochondrial mem-
brane.308 Other approaches include the
use of selenium,309 which is found in the
active site of the selenoprotein gluta-
thione peroxidase, or of melatonin,
which functions as an antioxidant.310
Future opportunities.We recently have
shown that the hypoxamir, miRNA 210,
can inhibit mitochondrial respiration in
trophoblast cells,311 hence opening the
door to targeted therapies to alleviate
mitochondrial dysfunction and oxida-
tive stress in the placenta. The male fetus
is at greater risk of adverse pregnancy
outcome (eg, preterm birth and still-
birth) than is the female fetus, although
it is unclear whether this is because the
male places itself at risk by its desire for
greater growth or if the female adopts a
conservative strategy to ensure success-
ful delivery and propagation of the spe-
cies.312,313 Sexual dimorphism occurs in
placental gene expression,314 particularly
of genes that are involved in the in-
ﬂammatory response, in response to
maternal adiposity and in diseases such
as preeclampsia. We found increased
expression of inﬂammatory and
apoptotic markers in placentas of male
fetuses from preeclamptic pregnancies
compared with female fetuses.315 Simi-
larly, we found differences in placental
expression of miRNA 210 and its mito-
chondrial target genes between male and
female fetuses of lean, overweight, and
obese women that were mediated by
differences in the transcription factor
NF-kB p50.305 Our current data there-
fore indicate that, in conditions such as
GDM, preeclampsia, and obesity, in-
ﬂammatory pathways are activated in the
placenta in a sexually dimorphic manner
to regulate the production of reactive
O2 and nitrogen species that lead to
oxidative/nitrative stress and to mito-
chondrial dysfunction (Figure 10). This
results in placental dysfunction and
adverse pregnancy outcome and suggests
that targeting of inﬂammatory pathways
might be a useful approach to preventoxidative stress. Dietary manipulation
(eg, inclusion of omega 3 fatty acids
and vegetables), the use of antiin-
ﬂammatories (eg, resveratrol) and
immune selective antiinﬂammatory de-
rivatives, or targeting strategies that
involve miRNA, siRNA, viral vectors,
nanoparticles, and biologics may prove
useful. These targeting strategies, how-
ever, may need to be different based on
the sex of the placenta.
Scientiﬁc gaps. Current gaps in the
knowledge include the absence of
proof of a cause-and-effect relationship
between oxidative stress and adverse
outcome. Perhaps an animal model of
induced oxidative stress with adverse
outcome would facilitate this. In addi-
tion, the tissue and cellular localization
and contribution of different sources of
oxidative stress (ie, including the gener-
ation and scavenging mechanisms of
ROS) must be studied comprehensively.
Further, the timing of the oxidative stress
insult, either early, mid, or late gestation
or continuously, on outcomes needs to
be considered when designing drug tar-
geting studies.
Identification of potentially useful
or experimental drugs to target
important
Challenges and advantages of rescuing
and repurposing (Christine Colvis,
National Center for Advancing
Translational Sciences)
Background. The most common reason
for an investigational drug to fail to make
it through the Food and Drug Adminis-
tration (FDA) approval formarketing is its
inability to demonstrate clinically mean-
ingful efﬁcacy in the disease being studied.
At the stage of phase 2 trials, another
major reason for failure is simply because
of business strategy decisions that result in
the deprioritization of a drug.316,317 In
either case, there is no scientiﬁc reason
that the drug could not be pursued for an
indication other than that for which it was
originally being developed.
National Center for Advancing Trans-
lational Sciences (NCATS) new thera-
peutic uses program. The new therapeutic
uses program uses a novel approach toJULY 2016 Amprovide academic researchers with ac-
cess to investigational drugs from phar-
maceutical companies.318 The program
leverages investments that have been
made by pharmaceutical companies in a
variety of drugs and biologics (agents)
but for which the company has often
times discontinued development. To
qualify for inclusion in the program, the
agent offered by the company has to have
been through at least a phase 1 clinical
trial, so that safety in humans has already
been assessed in at least 1 population. By
limiting the agents to only those that
have been tested in humans, the new
therapeutic uses program is able to move
projects quickly to phase 2a trials to test
the agents for efﬁcacy in new indications.
Under the program, the pharmaceutical
companies provide agents (clinical sup-
ply including matched placebo and
preclinical material, if needed) and the
data that will be needed to ﬁle an inves-
tigational new drug application with the
FDA to study the agent for the newerican Journal of Obstetrics& Gynecology S21
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Health (NIH) provides the ﬁnancial
support for phase 2a trials and, if needed,
phase 1b trials and/or preclinical studies.
The NIH and the pharmaceutical
companies are turning to the broader
research community to identify novel
uses for the agents. The value of this
strategy bore out when, as a pilot,
NCATS listed 58 agents provided by
companies in June 2012 and within
2 months received almost 160 pre-
applications with ideas of indications
that the agents might be used to treat.
Because of the limited time (12 months)
allowed under the program for preclin-
ical studies, pediatric trials were not
encouraged in the 2012 pilot. However,
in 2014, NCATS issued a new set of
solicitations or funding opportunity
announcements, and this time offered
an funding opportunity announcement
speciﬁcally for pediatric indications. The
companies, in turn, had identiﬁed those
agents that they believed could be
developed for a pediatric indication. In
general, it was expected that pediatric
trials would be proposed only when
there was no adult patient population
for the disease or for which the mecha-
nism of action of the drug might be
meaningful only if modulated at an
earlier stage in development than in
adulthood.
There are signiﬁcant challenges when
trying to repurpose an investigational
drug for a pediatric indication. Unlike an
FDA-approved drug, these drugs often
have been studied in only dozens or
maybe a few hundred adults. So, side-
effects have been documented for
only a small number of individuals.
Furthermore, the metabolism of drugs
can be very different in younger
individuals than in adults. We face
similar challenges when we think about
exposing a pregnant woman to an
investigational drug. Effects of drug
exposure in pregnant women generally
will remain unknown until after the drug
has been on the market for years or even
decades.
Current opportunities. The NCATS
intramural program offers several op-
portunities for collaboration. AlthoughS22 American Journal of Obstetrics& Gynecologyfunds are not offered, there are several
ways to access valuable resources and
expertise at no cost to our collaborators.
The intramural program that likely has
the most potential for repurposing drugs
for use in pregnant women is the
screening of the NCATS pharmaceutical
collection. Nearly 2750 small molecular
entities have been approved for clinical
use by the United States and in other
countries around the world. NCATS has
amassed a screening collection of 2500 of
these, along with approximately 1000
additional investigational compounds.
Because they have been approved for
clinical use, these drugs will have been
used in far more people than the inves-
tigational drugs that are used in the New
Therapeutic Uses program, thereby
providing a more comprehensive risk
proﬁle for the drugs. Collaborators
generally approach NCATS with a high
throughput screening compatible assay
as a ﬁrst step toward repurposing 1 of
these approved medications. Of course,
when a drug is ﬁrst marketed, often, the
only data available on fetal effects
generally will come from preclinical
data. The FDA encourages the use of
pregnancy exposure registries as a ﬁrst-
line strategy for gathering information
on drug exposure during pregnancy.
They have compiled a list of >60 regis-
tries to facilitate the gathering of valuable
data.319 Cross-referencing data from
such registries with ﬁndings from
in vitro assays that were used to screen
the NCATS pharmaceutical collection
may provide a strategy for repurposing
drugs to address placental health
indications.
Future opportunities. Repurposing both
investigational and approved drugs is a
strategy that is pursued currently in
small and large pharma and in
academia. The strategy is attractive to so
many because of the signiﬁcant cost-
savings that result from the use of
drugs for which so much early devel-
opment has been completed already. In
the case of repurposing drugs for use in
pregnant women, it would be expected
that the longer a drug has been on the
market, the more information we would
have on exposure during pregnancy.JULY 2016Unfortunately, the drugs that will fall in
this category will often be drugs for
which a generic is available, thereby
eliminating an enforceable use patent or
regulatory exclusivity. Currently, there
are no effective incentives to pursue a
new indication for a drug that is avail-
able as a generic, regardless of the indi-
cation, unless a unique formulation for
the drug is developed.320 Although this
is a barrier for all indications, it is
particularly unfortunate for pregnant
women, which is a population for which
the development of new drugs (investi-
gational drugs) is extremely unlikely.
Effect of pregnancy on drugs
pharmacokinetics and
pharmacodynamics (Maged M.
Costantine, MD, University of
Texas Medical Branch, Galveston)
Background. The use of medications
in pregnancy has been increasing pro-
gressively over the past 3-4 decades
(Figure 11).321-325 This is predominantly
because of changing in the de-
mographics of pregnant women,
because more women enter pregnancy at
a later age with increasing prevalence
of preexisting medical comorbidities
(such as diabetes mellitus, hypertension,
asthma, depression, and others) and
increased risk of obstetric complications
(eg, nausea and vomiting of pregnancy,
GDM, cholestasis of pregnancy, pre-
eclampsia.) that require pharmaco-
therapy.320-324 In a recent review, the
average number of medications this is
used by pregnant women is >4.320 This
increase in the use of medications is also
predominant in the ﬁrst trimester, where
almost one-third of pregnant women use
at least 4 medications.320 This is con-
cerning because the ﬁrst trimester is a
crucial period for organogenesis and
placental development that includes
trophoblast invasion, vascular remodel-
ing, and chorionic villi development; in
addition, many women are unaware of
their pregnancy status.320-324
Pregnancy physiologic changes and
their impact on medication pharmacoki-
netic and pharmacodynamics proper-
ties. Pregnancy is characterized by
signiﬁcant changes in the anatomy
FIGURE 11
Medication use during pregnancy
Secular patterns of use of any medication that was restricted to the first trimester at any time during
the period of 1976-2008. Average number of medications and proportion of women taking 4
medications (n ¼ 25,313) is shown.
Reprinted with permission from Mitchell et al.321
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which affect medications’ pharmacoki-
netic/pharmacodynamics properties
(Figure 12). Pharmacokinetic generally
refers to “what the body does to the
drug” and usually is described using the
drug’s absorption, distribution, meta-
bolism, and elimination; pharmacody-
namics refers to “what the drug does to
the body” and usually inﬂuences the
drug’s efﬁcacy and safety.326-330 Cardiac
output increases by 30-50% because of
both increase in heart rate and stroke
volume. Most of the increase occurs
early in pregnancy (75% by the end
of the ﬁrst trimester). The increase in
cardiac output is preferential in that
uterine blood ﬂow increases 10-fold
(17% of total cardiac output compared
with 2% prepregnancy), and renal blood
ﬂow increases 50%; there are minimal
alterations to the liver and brain blood
ﬂow.327,331 Cardiac output is further
increased during labor, with additional
300-500 mL of blood reentering the
circulation with every contraction. Both
systemic and pulmonary vascular re-
sistances decrease by 20-30%. Blood
pressure also falls toward the end of
the ﬁrst trimester and then rises again in
the third trimester to prepregnancy
levels. The increase in renal blood ﬂow
leads to a parallel increase in the
glomerular ﬁltration rate by approxi-
mately 40-65%.327,329,332 This can lead
to signiﬁcant increase (20-60%) in the
elimination rates of renally cleared
medications, which lead to shorter half-
lives and risk of subtherapeutic concen-
trations. Examples of these medications
include lithium, ampicillin, cefuroxime,
cefazolin, piperacillin, atenalol, and
digoxin.326,329
During pregnancy, maternal blood
volume increases by 40-50%, and total
body water increases to almost 8.5 L by
the end of pregnancy. In addition,
maternal fat stores and fat mass increase
by almost 10-fold. The increase in blood
volume and water within the body
expands the volume of distribution of
hydrophilic substances.333 On the other
hand, the increase in fat mass leads to a
larger volume of distribution of lipo-
philic drugs, such as sedatives. For some
drugs, a larger volume of distributioncould lead to decreased peak serum
concentration, which may necessitate a
higher initial and maintenance dose to
obtain therapeutic plasma concentra-
tions.329,334 Additionally, because of
the decrease in serum albumin during
pregnancy, highly protein bound com-
pounds (such as digoxin, midazolam,
and phenytoin) may display higher free
levels, which increases their peak
plasma concentrations.327,329 The hyper-
vascularity and edema of the upper res-
piratory mucosa theoretically may result
in an increased absorption of inhaled
agents such as corticosteroids.329,335 The
delayed gastric emptying and prolonged
small bowel transit time may alter the
bioavailability (decrease maximum con-
centration and time to maximum con-
centration) and thus decrease the efﬁcacy
of oral drugs that are taken as a single
dose because a rapid onset of action is
desired.329,336
Drug metabolism is also altered in
pregnancy, in part, because of elevated
sex hormones. In general, drug meta-
bolism occurs through phase IJULY 2016 Am(oxidation, reduction, or hydrolysis)
and/or phase II metabolism (glucur-
onidation, acetylation, methylation, and
sulfation). Cytochrome (CYP) P450
represents a family of enzymes and is a
major route of drug metabolism that is
affected by pregnancy (activity increased
for CYP3A4, CYP2D6, CYP2C9,
CYP2A6, and decreased for CYP1A2,
CYP2C19, and CYP2D6 subtypes). For
example, the increase in activity and
abundance of CYP3A4 in pregnancy lead
to an increase in the clearance of its
many substrates, such as nifedipine,
carbamazepine, midazolam, saquinavir,
indinavir, lopinavir, ritonavir, and many
others.337-340
In summary, maternal physiologic
changes affect the pharmacokinetic/
pharmacodynamics of drugs through
changes in the drugs’ absorption,
increasing the volume of distribution,
protein binding, renal clearance, meta-
bolism, and placental biodisposition.
Any novel drug that is identiﬁed to act on
potential placental molecular targets
must be evaluated in the context of theseerican Journal of Obstetrics& Gynecology S23
FIGURE 12
Factors that affect drug pharmacokinetics and pharmacodynamics in
pregnancy
Pregnancy induces major physiological changes that can affect the pharmacokinetic and pharma-
codynamic properties of medications.
CO, cardiac output; BP, blood pressure; HR, heart rate; NVP, nausea and vomiting of pregnancy; SVR, systemic vascular resistance.
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identiﬁed.
Current opportunities. Pregnant women
are still considered therapeutic orphans
because most current therapeutics were
never studied during pregnancy.341-343
In a recent review of the literature,
<2% of all pharmacokinetic studies
involved pregnant women.344 This is
concerning because the lack of data on
pregnancy-speciﬁc dosage of many
medications leads physicians to extrap-
olate drug dosage regimens from
nonpregnant subjects or men. This may
lead to over or under dosing and may
reduce efﬁcacy and increase risk of
toxicity. In view of these gaps, theS24 American Journal of Obstetrics& Gynecologyopportunities to study the pharmacoki-
netic properties of many currently
used medications with potential impact
on placental development and use
in selective targeting of molecular
pathways are involved in the patho-
physiology of various obstetrical com-
plications. This will lead to more
effective treatment of pregnant women,
while reducing the risks of adverse
events.341 The new FDA rule regarding
drug classiﬁcation represents a huge
current opportunity to encourage re-
search in this ﬁeld.
Future opportunities. A major obstacle to
studying medications (current and
novel) in pregnancy is the lack of systemsJULY 2016that allow researchers to determine the
safety and efﬁcacy of these medications.
Some researchers rely on in vitro
placental transfusion models; however,
these placentas typically are collected
after delivery, usually at term, and may
not represent the changes in drug phar-
macokinetic and pharmacodynamics
throughout the pregnancy. Others rely
on primate animal models; however,
they are usually expensive and hard to
work with. Future opportunities in this
ﬁeld include the development of novel
technologies to assess the placenta in
real-time and applying them to study
medication’s biodisposition in preg-
nancy. The use of novel ultrasound
techniques or other novel technologies
to tag drugs and then be able to image
the placenta and fetus to look for their
distribution would be a great future
opportunity.
Scientiﬁc gaps.Most therapeutics were
never studied in pregnancy during
development, because pregnant women
were excluded from such studies.341-343
In addition, their safety, tolerability, ef-
ﬁcacy, and dosing were extrapolated
from studies conducted in men or
nonpregnant women. This leads to un-
der or over dosing and affects efﬁcacy
and toxicity of these medications. There
exists a large gap in information
regarding medications pharmacokinetic
properties in pregnancy and during
lactation. The effects of placental trans-
porters and biodisposition enzymes
on medication pharmacokinetic and
pharmacodynamics, and transplacental
transfer represent a large gap in our
scientiﬁc knowledge. Moreover, the
inability to study placental transport
expected after delivery with delivered
placentas widens this scientiﬁc gap.
From bench to bedside: processes and
pitfalls translating research ﬁndings
into practice paradigms (David M.
Haas, Indiana University)
Background.When Vannevar Bushwrote
“Science: the endless frontier” in 1945, it
inspired that science would provide
solutions to health problems. It further
described how investment in scientiﬁc
research could serve as a vehicle to
FIGURE 13
Translational research peaks and valleys
This figure illustrates the multiple-step model (5 hills and 4 valleys) of translating research into
practice and public health benefit and the many “valleys of death” that can be encountered along the
way. Depicted are the 5 phases of translational research separating 4 valleys: basic discovery
science to research involving humans (T1), from human studies to evidence-based guidelines (T2),
from guidelines to health practice (T3), and from health practices to population health programs (T4).
Reprinted with permission from Meslin et al.345
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nation.345 It is against that backdrop that
the public holds out hope for scientiﬁc
inquiry. This promise engenders a social
contract that funding of scientiﬁc in-
quiry would be translated into better
health that can elevate the national good
on many levels.
The objectives of this portion of the
workshop were to describe the trans-
lational research spectrum and the dif-
ﬁculties with translating research into
practice, to articulate additional con-
cerns and difﬁculties with translational
research in pregnancy by highlighting
some translational successes in preg-
nancy research, and to propose some
mechanisms that are aimed at improving
the translation of ﬁndings into practice
and measuring research impact.
Translational research. The research
spectrum generally begins with basic
science ﬁndings that are then translated
to human and clinical research
(Figure 13). This is termed “T1” research
on the translational spectrum: the
translation of animal and basic science
research into humans.346 The “T2” step
in research translation is taking the
clinically relevant research ﬁndings and
translating them into practice guidelines
and having them become routine prac-
tice in health care.347,348 Some models of
the translational spectrum have included
more steps that can include the popula-
tion health impact and involvement of
consumers. All of the models serve to
help assess the success of translational
research at fulﬁlling the initial promise
to improve public health.
Globally, billions of dollars are spent
on biomedical, clinical, and health ser-
vices research, training of providers,
quality improvement initiatives, and
safety initiatives.347 However, it has been
demonstrated that, in the United States,
only 55% of patients receive the recom-
mended evidence-based care.349 Addi-
tionally, 20-30% of patients get care that
is not needed or could be potentially
harmful.350 This is a failure in translating
research ﬁndings into practice. Experts
have found that this can be due to system
failures. Grimshaw et al348 noted, “Sys-
tems fail to ensure that effective andcost-effective programs, services, and
drugs get to all those who need them
and providers fail to provide the level of
care they aspire to.”
An example of this is seen in the fact
that in 2010, the NIH spent $31 billion
on research. However, from 2006-2009,
only 74 new drugs were approved by the
FDA, which was only one-half the
number approved during the previous
epoch.351 One interesting study looked
at 101 promising technologies that were
published in the highest impact journals.
This report found that, in the 20 years
after publication, only 5 of these prom-
ising technologies were licensed for
clinical use, with only 1 angiotension-
converting enzyme inhibitor being used
regularly in clinical practice.352 The
report found multiple steps where these
promising technologies failed, were lost,
refuted, or neglected along the trans-
lational spectrum. It has also been found
that promising technologies take a long
time to get into routine practice, at times
up to 17 years.345 These areas of trans-
lational failure have been coined the
translational valleys of death.344 The
translational valleys of death can come
from regulations that impede research orJULY 2016 Ampractice, costs, limited resources,
commercialization issues, broad social
policy implications, professional stan-
dards, governmental policy, and general
science policy.344 There are many places
where potential health-improving
research ﬁndings can become derailed.
The key is to overcome these difﬁculties
and cross the translational valleys of
death.
Translational research in pregnancy.
Translational research in pregnancy
holds additional potential pitfalls that
generally ﬂow from the concerns for the
impact of therapies on developing babies
and potential long-term impacts that
may be unrecognized for years after
birth. It is for this reason that, for many
years, pregnant women were actively
excluded from research. There are
several examples in which translational
research failed to detect problems, lead-
ing to major public health consequences.
In 1956, thalidomide was introduced as a
“wonder drug” in Germany.353 It was
purported to be a treatment for nausea
and vomiting, insomnia, coughs, colds,
and headaches. Early studies in mice and
rats did not demonstrate congenitalerican Journal of Obstetrics& Gynecology S25
Supplement Obstetrics ajog.organomalies; therefore, it was used as a
sedative and tranquilizer in early preg-
nancy. However, in 1961, reports sur-
faced of severe congenital anomalies that
included limb reduction defects that led
to its rapid withdrawal from the market.
This was a clear failure of T1 research.
Two notable examples of failure in T2
research in pregnancy have been seen
recently. The withdrawal from the mar-
ket of the combination drug Bendectin
was done because of lawsuit pressure
regarding congenital anomalies.354 The
drug was used by a large proportion of
pregnant women for nausea and vomit-
ing in early pregnancy. However, no re-
ports of defects were proved. Without an
alternative, women suffered. The rates
of hospitalization for severe dehydration
from hyperemesis gravidarum rose
dramatically. This was an example of
where research demonstrated safety and
practice patterns were established, but
fear and a lack of a supportive response
to the public caused the withdrawal of
an effective therapy, which led to a
negative public health impact. Even
more recently, the poor adoption rates of
the effective human papilloma virus
vaccines to prevent cervical cancer is
another example of success at the T1
stage, but unfortunately a failure at the
T2 stage.355 Despite proven efﬁcacy and
safety and coverage by the Children’s
Immunization Program, vaccination
rates of the target populations remain
low.
However, there are some noteworthy
translational successes in pregnancy. The
development of Rhogam to prevent Rh
isoimmunization came about from a
conﬂuence of observations along the
translational spectrum. After demon-
strating efﬁcacy and safety in clinical
trials, it has been adopted universally as a
standard of care preventive therapy in
pregnancy, saving thousands of babies
every year.356,357 In similar ways, ante-
natal corticosteroids for accelerating
fetal lung maturity in threatened pre-
term birth have been a translational
success story in obstetrics.358 From
astute observations in sheep to landmark
clinical trials in humans and pivotal
metaanalyses, antenatal corticosteroids
are now used routinely on labor andS26 American Journal of Obstetrics& Gynecologydelivery units and clearly have reduced
the rates of mortality in preterm
newborn infants.359-361 This was greatly
aided by NIH Consensus Conferences
highlighting the beneﬁts and safety of
the therapy.362
How to improve translational success.
Many have proposed systems that are
aimed at crossing the translational val-
leys of death. One unifying theme is
aimed at getting stakeholder investment
in the translational process. Practicing
providers, the public, industry, and reg-
ulatory/governmental agencies must
have a stake in the translational processes
along the way if there is any hope of
translating important research ﬁndings
into practice aimed at improving the
public health.347,363-365 Otherwise, fail-
ure at T2 and beyond can occur
commonly. The formation of trans-
lational teams that involve the stake-
holders can ensure involvement from the
beginning and should involve the entire
translational spectrum.344,347 Effective
dissemination of the impact of trans-
lational research can inform those
providing funding and the public as to
the public good that is being gained.
Psychology of change research has
noted 3 stages of practice change:
awareness, acceptance, and adoption.366
Most translational research focuses on
the ﬁrst 2 stages, whereas the reason that
most promising therapies fail to realize
their public health impact is the failure of
“adoption” into practice. A provider may
know that research shows a beneﬁt and
accept that it might help the patients, but
there may be obstacles to getting it into a
routine practice pattern; thus, it is not
adopted. This is because “adoption”
takes different pathways in the brain
before these cognitive changes become
embedded in practice.365
A focus on stakeholders and align-
ment of incentives can help with the
adoption into practice. Dissemination of
the impact of research ﬁndings is crucial
to get stakeholder enthusiasm. For
instance, the Human Genome Project
turned a $4 billion government invest-
ment into $796 billion in economic
growth.367 Translational teams, like
those stimulated by the NIHClinical andJULY 2016Translational Science Awards, focus on
collaboration and development of net-
works of scientists, stakeholders, and
regulatory agencies in an effort to propel
translational science across the valleys of
death and into practice.368,369
Speciﬁc to pregnancy, there is a
tremendous need for public involve-
ment, education, and advocacy. The
focus of protection of mothers and in-
fants through research, instead of from
research, should be highlighted. Ethicists
and children’s advocacy groups should
also be engaged. The advent of individ-
ualized therapeutics and diagnostics
are forcing this conversation to accel-
erate.370 In addition, the utilization
of biorepositories can help stimulate
this translational process by focusing
on potential pooled resources and
collaborations.
In conclusion, bridging the trans-
lational research gap from bench to
bedside has many potential pitfalls.
Pregnancy translational research has had
well-documented missteps but several
important success stories as well.
Although research to cross the trans-
lational “valleys of death” is difﬁcult,
using what is known about behavior
change will be important in ultimately
fulﬁlling the promise of scientiﬁc
research funding to improve public
health and the public good. Thinking
broadly about stakeholders and in-
volving these stakeholder teams in the
processes across the translational spec-
trum can help cross the valleys of death
and help take promising discoveries
from bench to bedside.
Current opportunities. Individualized
pharmacotherapy provides opportunities
currently to tie genomic and other
“-omic” technologies to ongoing clinical
trials. In addition, the development and
utilization of saved samples from past
trials and biorepositories provide a wealth
of opportunities for analyses using cutting
edge technologies to assay for biomarkers
that can serve as therapeutic monitoring
or individualized pharmacotherapy
model development aids for patients. The
focus on diagnostic and therapeutic
studies in humanmodels and humans is a
clear priority moving forward.
FIGURE 14
Schematic of extracellular microRNAs derived from human trophoblasts
MicroRNAs can be released from the trophoblast layer in different forms: microvesicle-enveloped
form; apoptotic bodyeenveloped form; nano-sized, exosome-encapsulated form; and RNA-
binding, protein-bound form. Exosomes are formed by budding in intraluminal vesicles to form
multivesicular bodies. Multivesicular bodies fuse with the plasma membrane and release their
intraluminal vesicles as exosomes into the extracellular space. In contrast, microvesicles are pro-
duced directly by budding and the detachment of membrane vesicles from the plasma membrane.
Apoptotic bodies (blebs) derive from cells that are undergoing apoptotic fragmentation and the
formation of membrane-enclosed vesicles.
miRNA, microRNA.
Reprinted with permission from Ouyang et al.395
Ilekis. Potential placental molecular therapeutic targets. Am J Obstet Gynecol 2016.
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future should have clear response bio-
markers, pharmacokinetic/pharmaco-
dynamic/pharmacogenomic outcomes,
and harmonized efﬁcacy outcome mea-
sures in this ﬁeld. This will help evaluate
molecular targets more robustly with
fewer trials and may help us evaluate
promising technologies in a more cost-
effective manner. Requiring all diag-
nostic and therapeutic trials that
receive funding to have these types of
outcomes and measures will focus
investigators.
Scientiﬁc gaps. The plethora of basic sci-
ence data accumulating about placental
development and the interface between
mother and fetus must be linked clearly
to diagnostic and/or therapeutic needs.
In addition, because there is not perfect
animal model, there needs to be a way to
study these on human placental models
as often as possible. Another clear gap in
much of the therapeutic research in
pregnancy is a lack of long-term follow
up of the infant. Ensuring funding for
follow-up studies, including potential
“-omic” studies, of the offspring should
be a priority.
Evolving technologies for placental
specific therapeutic drugs
Trophoblastic nanovesicles, miRNA,
and their function (Yoel Sadovsky,
MD, Magee-Womens Research
Institute)
Background. Coordinated communica-
tion among cells and tissues is critical
for development, homeostatic func-
tion, and adaptation to change. The
trafﬁcking of information between the
fetoplacental and maternal compart-
ments is essential for fetal develop-
ment, growth, and pregnancy health. It
also serves to reduce maternal-fetal
conﬂicts and to balance biologic re-
sources for the beneﬁt of the 2 organ-
isms. In past years, it was believed that
communication between the fetopla-
cental unit and the mother was
executed by hormones and growth
factors, which are soluble in the blood
or are bound by protein carriers, and
serve as paracrine or endocrine signals
that control pregnancy health. It is nowclear that nucleic acids, and particularly
sRNA molecules, trafﬁc among tissues
and impact cell biology.
MiRNAs and extracellular nanovesicles. A
major class of these noncoding RNAs,
and 1 of the best studied, is the family of
small regulatory RNAs called miRNA.
MiRNAs originally were described in the
nematode Caenorhabditis elegans and
were later found in the genome of many
organisms, including humans. They
are single-strand RNA molecules of
20-24 nucleotides that characteristically
repress gene expression by guiding an
RNA-induced silencing complex to a
target RNA, with subsequent attenuation
of gene expression by the inhibition
of mRNA translation and/or mRNA
degradation.JULY 2016 AmIt has become clear recently that, in
addition to the effect of miRNAs on
intercellular gene regulatory networks,
miRNAs are also packaged within
extracellular vesicles, where they can be
trafﬁcked to local and distant cell types
(Figure 14). Transport within extracel-
lular vesicles may provide substantial
advantages, including stability, intravas-
cular processing, and selective delivery
to target cells.371-373 Diverse cell types
(eg, hematopoietic cells, mast cells,
platelets, neurons) produce and release
extracellular vesicles, which can be
found in the blood, urine, saliva, breast
milk, amniotic ﬂuid, ascites, cerebro-
spinal ﬂuid, bile, lymph, tears, and
semen.374-377 These vesicles are charac-
terized by their size, shape, and con-
tent.378 Importantly, when released toerican Journal of Obstetrics& Gynecology S27
FIGURE 15
Schematic depicts the exosome-mediated induction of viral resistance
Chromosome 19 microRNA clusters were transferred to recipient cells. Primary trophoblast cells
release exosomes that contain chromosome 19 microRNA clusters, which are taken up by recipient
cells, thereby mediating chromosome 19 microRNA clusteredependent autophagy. Incoming viral
particles (red) are likely trafficked in endocytic vesicles from the endosomal pathway into preexisting
autophagosomes, which then fuse with lysosomes to form autolysosomes, as a mechanism to
degrade these virus-containing vesicles. The gray arrows indicate the stepwise trafficking of
trophoblast exosomes and viral particles to a recipient cell.
AL, autolysosomes; APs, autophagosomes; C19, chromosome 19 microRNA clusters; EXO, exosomes.
Reprinted with permission from Delorme-Axford et al.417
Ilekis. Potential placental molecular therapeutic targets. Am J Obstet Gynecol 2016.
Supplement Obstetrics ajog.orgthe extracellular space, these vesiclesmay
target local and distant cell types, and
release nonhormonal signals that control
physiologic condition, determine disease
risk, and even harbor therapeutic po-
tential.379-382 The major types of extra-
cellular vesicles include apoptotic blebs,
microvesicles, and exosomes, each pro-
duced by different pathways. Apoptotic
blebs (500-4000 nm in diameter) are
formed during partial or complete cell
death and disintegration and contain
cell organelles and cytoplasmic proteins
that are subsequently cleared from the
circulation by macrophages.377,383,384
Microvesicles (100-1000 nm in diam-
eter) originate from outward buddingS28 American Journal of Obstetrics& Gynecologyand ﬁssion of the plasma membrane,
where microdomains and associated
protein cargo are enveloped for direct
cellular exit.385-389 Exosomes (40-150 nm
in diameter) originate from the intracel-
lular endosomal network through serial
processes that are initiated by the
enrichment of endosomal membrane
complexes by tetraspanins and other
proteins.390,391 This is followed by
budding of intraluminal vesicles within
multivesicular bodies (MVBs) and sub-
sequent movement to the plasma mem-
branes, where multivesicular bodies fuse
with the cell membrane to release
actively intraluminal vesicles as extra-
cellular exosomes.377,392 Among allJULY 2016extracellular vesicles, exosomes have
been studied extensively in recent years
because of their ability to modulate
target cell physiology, immune function,
and carcinogenesis.393 Exosomes also
harbor miRNAs as part of their
cargo.371,394,365
We and others recently have charac-
terized the trophoblastic miRNA
landscape and the potential role
of trophoblastic miRNA in fetoplacental
to maternal communication.393-397
Whereas exosomes are found in the
circulation of pregnant women, little
is known about trophoblastic exo-
somes. Many studies on extracellular
vesicles in pregnancy have associated
a mixture of vesicles (exosomes,
microvesicles, apoptotic blebs) with
disorders of pregnancy, thus blurring
some the distinct properties of these
vesicles.398-401 Placental exosomes have
been implicated in several discrete
functions, such as immune modula-
tion,402-404 where exosomal cargo pro-
teins, such as galectin-3405 and human
leucocyte antigen-G,406 may perform an
immune modulatory function. 407 Other
exosomal cargo molecules, such as Wnt/
b-catenin, ﬁbronectin, and prostaglan-
dins, may play a role in supporting ho-
meostasis throughout pregnancy.408-413
We have shown that the miRNA
landscape within the cargo of human
trophoblastic exosomes is nearly iden-
tical to that of villous trophoblasts.396
The most abundant trophoblastic
miRNA species are those derived from
the chromosome 19 miRNA cluster
(C19MC),396,414 which is the largest
miRNA cluster in the human genome,
spanning approximately100 kb of
genomic DNA and harboring 46 intronic
miRNA genes that express 58 miRNA
species.396,413,415,416 Importantly, we
found that, in comparison with non-
trophoblastic cells, primary human tro-
phoblasts are resistant to infection by
diverse types of DNA and RNA viruses,
which include clinically relevant species
such as herpes simplex virus type 1,
rubella, HIV, and cytomegalovirus, but
not the nonviral pathogens Listeria
monocytogenes and Toxoplasma gon-
dii.393,417-419 A remarkable ﬁnding was
that the viral resistance could be
ajog.org Obstetrics Supplementtransferred to other, nonplacental pri-
mary cells and cell lines by exposing
these cells to a medium that was pre-
conditioned by primary human tro-
phoblasts or to exosomes that are
produced in human trophoblasts
(Figure 15). We also found that this
effect was mediated, at least in
part, by exosome-packaged C19MC
miRNAs.393,396 Cells transfected with
a bacterial artiﬁcial chromosome that
harbors the C19MC locus or with
individual, highly expressed C19MC
miRNAs also became more resistant to
viral infections. Our data showed that
this effect of exosomal C19MC miRNAs
was mediated by the stimulation of
autophagy in recipient cells and that
pharmacologic or genomic inhibition of
autophagy diminished the conferral of
antiviral response to recipient cells.393
Although C19MC miRNAs likely act in
concert with other antiviral responses,
our data pointed to a unique and
transferrable antiviral response that is
mediated by human trophoblast-derived
exosomes.
Although the mechanisms, dynamics,
and targets of miRNA-containing
trophoblastic exosomes remain un-
known, our recent human and mouse
data suggest that trophoblastic C19MC
miRNAs are transferred primarily from
trophoblasts to maternal tissues. This
is plausible, because trophoblasts are
bathed directly in maternal blood yet
separated from the fetal blood by a
basement membrane and endothelial
cells. Together, these analyses shed new
light on miRNA-based communication
among the fetoplacental and maternal
compartments. Importantly, our data
suggest an extraordinary means of
nonhormonal communication between
the placenta and the maternal-fetal
compartments, which suggests a critical
role for miRNAs in pregnancy health.
Current opportunities. Although it is
clear that the plasma contains several
types of extracellular vesicles, their mo-
lecular and metabolic cargo are largely
unknown. Moreover, our understanding
of the function of these vesicles is rudi-
mentary. The formation of the placenta
during pregnancy adds a new source ofextracellular vesicles to the maternal
blood stream and possibly to the
fetal compartment. Whereas C19MC
miRNAs are packaged distinctly within
these placental vesicles, it is not clear
whether there are other, placenta-
speciﬁc, molecules and signals that are
packaged within vesicles. Importantly,
modern technology enables us to sepa-
rate the different types of vesicles and to
associate them with disorders of preg-
nancy that reﬂect placental function. It is
also possible that the state of pregnancy
changes the repertoire of extracellular
vesicles that are produced by maternal
tissues, thus adding to the landscape of
pregnancy-related extracellular vesicles.
This creates a new opportunity to catalog
these vesicles, assess their origin, con-
tent, and cellular targets and to deﬁne
the normal landscape of extracellular
vesicles (the “vesiculome”) throughout
human gestation.
Future opportunities. The development
of new tools to isolate extracellular
vesicles efﬁciently may allow us to
examine local and systemic targets of
trophoblastic extracellular vesicles and
whether their cargo faithfully informs
the health of trophoblasts. It may also
allow us to identify target cells and
interrogate the impact of pregnancy-
speciﬁc extracellular vesicles on these
cells in health and disease. Although
initial work has centered primarily on
maternal tissue targets, future research
may focus on intraplacental paracrine
targets and fetal targets of placental
extracellular vesicles. These opportu-
nities, coupled with recent de-
velopments in understanding of miRNA
function, will require the development
of innovative label-free technologies to
collect and sort extracellular vesicles,
which will shorten the time to clinical
translation and potentially offer a dra-
matic improvement in our ability to
assess placental health dynamically
throughout pregnancy using maternal
blood tests. Knowledge in this ﬁeld may
also stimulate the development of
nanovesicles as carriers of noncoding
RNAs, drugs, and chemicals that selec-
tively target placental cells for thera-
peutic purposes.JULY 2016 AmScientiﬁc gaps. The current and future
opportunities that were summarized
require us to bridge pertinent knowledge
gaps. We must understand the process of
cargo loading to diverse trophoblastic
vesicles and the potential selectivity of
this process. This should be followed by
analysis of the mechanisms used by
trophoblastic exosomes to enter target
cells selectively and impact their biologic
condition. The current state of perinatal
science raises additional questions:
Do surface and cargo proteins within
trophoblastic extracellular vesicles play a
role in this process? What determines
targeting by extracellular vesicles? Can
fetal vesicle-bound or free miRNAs and
other types of RNA molecules cross the
placenta into the maternal circulation
and inform on the health of fetal tissues?
How early in gestation can we ﬁnd and
isolate placental extracellular vesicles
and RNA from maternal blood? The
answers to these and related questions
will greatly impact the ﬁeld of placental
biology and its translation to pregnancy
diagnostics and therapy.
Aberrant regulation of myometrial
contractility by maternal cell-free
plasma (CFP) RNA of placental origin:
screening and therapeutic implications
(Carl P. Weiner, MD, University of
Kansas School of Medicine)
Background. The CFP transcriptome is
altered by numerous disorders, often
reﬂecting the stage of disease develop-
ment.420 Although the biologic roles of
these coding and noncoding RNAs are
unclear, they are not simply cellular
debris. Synthesized and released by a
range of cells that include human cho-
rionic villi, their biologic stability and
target tissue speciﬁcity are thought to
reﬂect their release within either exo-
somes or shedding vesicles or attached
to argonaute 2 proteins.421 Cell-to-cell
transfer and their ability to function
once transferred are shown in studies
that used mRNA/miRNA-loaded extra-
cellular vesicles and protein com-
plexes.422-424
Based predominantly on studies of
symptomatic women, spontaneous pre-
term birth (sPTB) is considered an
inﬂammatory process.428 We measurederican Journal of Obstetrics& Gynecology S29
Supplement Obstetrics ajog.orgboth the mass restricted (MR) score and
IL-6 in 1004 consecutive amniotic ﬂuid
samples at 16 weeks from healthy preg-
nancies with known outcomes (unpub-
lished data). Ten percent delivered at
<37 weeks gestation; 4% delivered at
<32 weeks gestation. Nineteen percent
had an MR score of 1; 2% had an MR
score of 3 or 4, which indicated signiﬁ-
cant inﬂammation. However, there was
no relationship between either sPTB or
preterm premature rupture of mem-
branes and the MR score; 23 of 27
deliveries at <28 weeks gestation
occurred to women with an MR score of
0. IL-6 levels increased as the MR score
rose (0 ¼ 102 pg/mL; 3 ¼ 451 pg/mL,
and 4¼ 706 pg/mL) but was unrelated to
subsequent sPTB. Whatever the role of
inﬂammation in preterm or term birth,
it seemingly occurs after 20 weeks
gestation.
We proposed in 2011 that mRNA and
miRNA were candidate mechanisms for
the regulation of myometrial quiescence
activation (unpublished data) and have
been testing the hypothesis that CFP
RNAs enable communication between
mother and pregnancy and that, as a
direct result, changes in the maternal
CFP transcriptome predict both the
occurrence and mechanism of sPTB.
Methodologic reﬁnements. In 2007, we
developed an extraction method that
yielded increased quantities of both CFP
nucleic acids and proteins in a single
process. The typical yield of total
RNA extracted is 18-35mg/mL plasma,
enabling comprehensive, transcriptome
wide study with the use of multiple
microarrays and/or next-generation
sequencing, plus the conﬁrmatory po-
lymerase chain reaction studies all on the
same patient plasma sample.
To speed marker validation and
facilitate translation into the clinical
arena, we developed a series of tech-
niques that included economical, high-
throughput gene quantiﬁcation that
allows for the running of panels of genes
to predict sPTB within a few hours.
The method allows us to run all
controls necessary for marker quantiﬁ-
cation in a single polymerase chain
reaction well.S30 American Journal of Obstetrics& GynecologyThe CFP transcriptome is altered in
women destined for sPTB by 16 weeks.
Using longitudinally obtained banked
plasma samples from women with
known pregnancy outcomes and
microarray/next-generation sequencing,
we identiﬁed and conﬁrmed >90 novel
CFP RNAs in the plasma of women who
were destined for sPTB between 26-32
weeks gestation; some of the marker
expressions were altered as early as
16 weeks gestation. In a second cohort,
we found that several markers that were
abnormal at 16 weeks gestationwere also
abnormal at 12 weeks gestation. We then
determined that 5 CFP markers were
known from studies of other cell systems
to interact with 7 myometrial gene/gene
products belonging to a previously
identiﬁed cluster of genes: the preterm
initiator set.425 Five of the 7 myometrial
genes were involved with the regulation
of intracellular calcium.
CFP RNAs originate from the pla-
centa.We next sought the anatomic
origin of the 5 CFP RNA markers; each
was dramatically overexpressed in the
placenta of women with <33 sPTB
weeks gestation, but not the placenta of
women delivered prematurely absent
labor and of women delivered at term in
labor.
CFP RNAs markers of sPTB can regulate
myometrial contractility.We then focused
on 1 particular CFP mRNA biomarker,
apolipoprotein, that, in silica, interacted
with the interferon gamma receptor,
which in turn interacted with 4 addi-
tional preterm initiator genes. Over-
expression of apolipoprotein in human
pregnant myometrial cells increased
both intracellular calcium ﬂux and cell
contractility. The addition of interferon
gamma receptor siRNA blunted the
stimulatory effect of apolipoprotein,
which demonstrated that interferon
gamma receptor was at least 1 of the
targets of the apolipoprotein mRNA.
Current opportunities. These ﬁndings
support the often stated premise that
sPTB is a result of placental dysfunction.
Speciﬁc CFP RNAs are released from
the placenta of women who are destinedJULY 2016for sPTB at <33 weeks gestation by the
end of the ﬁrst/beginning of the second
trimester that interfere with myometrial
quiescence, thus potentially creating
an environment that favors sPTB. The
early pregnancy time frame suggests
that effective therapy will require early
detection and initiation, which is
consistent with the general failure of
available tocolytic agents. It highlights
the preeminent importance of eluci-
dating the events that are involved in
human implantation and early placen-
tation. As such, the sPTB studies
described may serve an investigational
paradigm for the other great pregnancy
syndromes such as preeclampsia and
hypoxia that are associated FGR and
perinatal brain damage.
The ﬁrst task along the path to un-
derstanding human placentation is
descriptive: the creation of an appro-
priately sized research medical center
network for sample processing (using
new and established biobanks) for the
rapid construction of an “omics” atlas of
“normal” from the time period covering
implantation through at least 16 weeks
gestation. Such an atlas would serve as a
basis for all future research and generate
a host of new targets for hypothesis-
based testing in vitro using systems
similar to those described earlier.
Future opportunities. Real-time assess-
ment of the human placenta all but re-
quires noninvasive methods that may
not exist presently or have not yet been
applied to the study of the placenta. So
much about human placental function is
shrouded by darkness that the areas for
investigation are almost unlimited, each
with the potential for making a contri-
bution. Yet, it is highly likely that much
placental dysfunction has its foundations
set by the early second trimester and that
it is here that new insights are needed
desperately. The application of newer
organ on chip technology could allow
the testing of potential interventions
that will be identiﬁed during atlas con-
struction.426 Real-time approaches will
require either new imaging modalities
or be “omics” in nature. As discrete
markers of placental function linked to
speciﬁc disease phenotypes emerge, it
FIGURE 16
Translational steps for the development of nanoparticles for placental
drug delivery
Nanoparticles may contain therapeutic, diagnostic, and/or targeting components. In vitro, ex vivo,
and in vivo models will be used to investigate proof of concept and safety before clinical trials.
Ilekis. Potential placental molecular therapeutic targets. Am J Obstet Gynecol 2016.
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from a minimum of a laboratory work
day to less than a few hours, providing
near real-time feedback for nonimaging
modalities.
Scientiﬁc gaps. There are presently no
targeted pharmacologic therapies for
placental abnormalities. The fact that a
placental-derived CFP RNA that is
unique to women who are destined for
sPTB at <33 weeks gestation modulates
a myometrial gene that is associated with
sPTB and that its inhibition with siRNA
reverses the up-regulation demonstrates
that therapeutic targets can be identiﬁed
with current transcriptomic approaches.
It is likely that attempts to address
placental dysfunction after its establish-
ment will be of modest impact. Future
efforts should build on the knowledge
derived from atlas construction to seek
targeted therapies that enhance implan-
tation and early placental development.
Nanoparticles for placental drug
delivery (Erik Rytting, University of
Texas Medical Branch, Galveston)
Nanomedicine. The ﬁeld of nano-
medicine includes nanoparticles for
medical diagnostics, nanoparticles for
therapeutic delivery, and particles play-
ing both roles, referred to as theranostic
nanoparticles (Figure 16).427 Types of
nanoparticles that are used in therapeu-
tic delivery include liposomes, solid lipid
nanoparticles, polymeric nanoparticles,
polymeric micelles, dendrimers, and
polymeric DNA or siRNA complexes
called polyplexes.428 Advantages of
nanoparticles for drug delivery include
improved bioavailability, protection of
therapeutic payload, controlled release,
and increased drug targeting efﬁ-
ciency.429 Targeting ligands such as an-
tibodies, peptides, aptamers, or small
molecules can be conjugated or adsor-
bed onto the surface of nanoparticles to
promote the accumulation of the parti-
cles in speciﬁc regions or tissues that are
facilitated by binding of the targeting
ligands to a particular receptor.430
Nanoparticle characterization and bio-
compatibility. Characterization of drug-
loaded nanoparticles typically includesassessments of particle size, zeta poten-
tial (surface charge), encapsulation efﬁ-
ciency, and drug release kinetics. Particle
size and surface charge can have a
signiﬁcant effect on both particle distri-
bution and cellular uptake. Encapsula-
tion efﬁciency represents the mass of
drug actually encapsulated within a
nanoformulation as a percentage of the
intended drug loading. The drug release
proﬁle will demonstrate whether sus-
tained delivery of the drug from the
nanoparticles can be anticipated, which
can reduce dosing frequencies. It has
been demonstrated that drugs and pro-
teins are still pharmacologically and
biologically active after their release from
nanoparticles.431,432
Biocompatibility is an important
consideration in the development of
nanoparticles for therapeutic delivery.
The nanomaterial excipients themselves
must not elicit toxic responses such
as inﬂammation or oxidative stress.
Many of the polymeric nanoparticlesJULY 2016 Amdeveloped in our laboratory are based on
lactic acid polymer. When this polymer
breaks down within the body, the so-
called degradation product is lactic
acid, a naturally endogenous compound.
Transport of nanoparticles across the pla-
centa. To predict placental drug and
nanoparticle transport, our laboratory
focuses primarily on 2 experimental
models: the BeWo b30 human tropho-
blast cell line and the dually perfused
human placental lobule. Our compara-
tive study demonstrated excellent cor-
relation between the in vitro BeWo cell
line model and the ex vivo perfused
human placenta model in the prediction
of the transplacental transport of 4
model compounds.433 A separate study
then expanded the comparison with
placental transport data in the literature
and reported a strong correlation (cor-
relation coefﬁcient ¼ 0.95) between the
in vitro relative transfer rate and the
ex vivo transfer index.434 Botherican Journal of Obstetrics& Gynecology S31
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able for nanoparticle transport studies as
well. For example, the transplacental
transfer of polymeric nanoparticles has
been shown to be size-dependent in both
models, and limited transfer of silica
nanoparticles was demonstrated in both
BeWo cell and placental perfusion ex-
periments.435-437
Additional studies have shown that
gold nanoparticles do not cross the term
human placenta, that the transplacental
transport of poly-amidoamine den-
drimers is limited, and that liposome
transport across the placenta is size-
dependent.438-440 The observed size
dependence of nanoparticle transport
has been extended to demonstrate
increased drug transport across placental
trophoblast cells when the drug is
encapsulated in smaller polymeric
nanoparticles (diameter, 146 nm)
compared with larger nanoparticles
(diameter, 232 nm).441 Literature re-
ports of nanoparticles that have been
administered to pregnant rodents have
included titanium dioxide nanoparticles,
silica nanoparticles, zinc oxide nano-
particles, iron oxide nanoparticles, and
gold nanoparticles; results vary depend-
ing on particle size, surface charge, and
gestational age.442-446
Targeting strategies. Strategies for tar-
geted delivery of nanoparticles to the
placenta include the identiﬁcation of
peptides by phage display.447,448 Re-
searchers have reported enhanced
transcellular transfer of T7 bacterio-
phages across BeWo cells with an
integrin-binding amino acid sequence
peptide. Harris et al used a similar
approach in pregnant mice and identi-
ﬁed two peptides with increased
placental binding, designated as amino
acid sequence consisting of
CRGDKGPDC and KRK (unpublished
data).448 Kaitu’u-Lino et al449 designed
bacterial-derived nanocells that are
coated with antibodies to epidermal
growth factor receptor. The uptake of
these epidermal growth factor
receptoretargeted delivery vehicles in
ex vivo human placental explants was
greater than that of nontargeted nano-
cells. We have synthesized polymericS32 American Journal of Obstetrics& Gynecologynanoparticles conjugated with folic acid
to take advantage of the relatively high
expression of folate receptors in the
placenta. This has resulted in greater
cellular uptake and transport of the
nanoparticles across BeWo cells.
Current opportunities. Immediate appli-
cations of these technologic advances
include fetal drug therapy and placental
therapy. Although medication during
pregnancy is most often prescribed to
treat maternal conditions, there are a
number of fetal diseases for which a
targeted, transplacental delivery strategy
potentially could attenuate the adverse
maternal side-effects that are associated
with current treatment modalities.
These include fetal cardiac arrhythmias,
congenital adrenal hyperplasia, and fetal
thyroid disorders.450 Targeted drug de-
livery to the placenta itself could also
improve therapeutic options for
malaria-infected placenta or prevent
mother-to-child transmission of HIV.451
Future opportunities.Nanotechnology
has also been suggested for placental
diagnostic applications.452 Opportu-
nities abound for the development of
nanoparticle-mediated biosensors and
imaging agents, and it is likely that many
recent advances in cancer diagnostics,
for example, can be utilized to monitor
the structure and function of the human
placenta.453 As progress towards these
goals continues, it is imperative that the
biocompatibility of such nanomaterials
is investigated thoroughly to prevent
unintended consequences of fetal expo-
sure to any potentially harmful imaging
agents. For example, gadolinium-based
magnetic resonance imaging contrast
agents are not recommended for use
during pregnancy because of concerns
for nephrogenic systemic ﬁbrosis.454
Scientiﬁc gaps. Steps to translate the
preclinical promises of this technology
towards clinical trials and clinical prac-
tice will include scaling proof-of-
concept results from in vitro and small
animal studies to larger animal models
with placental structure and function
more similar to human placenta. For
example, recent progress has been madeJULY 2016to establish the pregnant baboon as a
nonhuman primate model for pharma-
cokinetic investigations.455-460 There is
also a need to reﬁne the pool of potential
placental targeting moieties to minimize
off-target nanoparticle distribution.
Side-effects can be averted when the
disbursement of medication to off-target
sites is reduced. A necessary, but
exciting, task will be to determine the
magnitude of dose reductions that are
possible when targeted therapeutic
strategies are applied. Nanoparticle-
mediated delivery to the placenta offers
tremendous beneﬁts for maternal-fetal
medicine.
Maternally sequestered delivery
systems for prevention of fetal drug
exposure (Gene Bidwell, University
of Mississippi Medical Center)
Background. Preeclampsia is a common
hypertensive disorder of pregnancy and
is one of the leading causes of maternal
and fetal morbidity and death. There is
currently no effective intervention for
preeclampsia short of induced delivery,
which makes it a leading cause of
premature birth. Improvements in
preeclampsia management have been
largely stiﬂed because of deleterious
effects of proposed small-molecule
therapeutics on the developing fetus.
The objective of our studies was to
develop a drug delivery system capable of
stabilizing novel therapeutic agents in
thematernal circulationwhile protecting
them from entering the fetal circulation.
The use of a biopolymer drug carrier to
prevent drug transfer across the pla-
centa. The major focus of our research
group is to develop drug carriers capable
of preventing placental transfer and fetal
exposure to therapeutic agents. Protein
transport across the placental barrier is
highly regulated, and proteins that are
not substrates for active transporters
rarely cross into fetal circulation. To take
advantage of this, we are using a protein-
based biopolymer to fuse to therapeutic
agents and sequester them in the
maternal circulation (Figure 17). This
biopolymer, termed elastin-like poly-
peptide (ELP), is based on a repeating
sequence found in human elastin.461
FIGURE 17
Model of the elastin-like polypeptide drug delivery vector
Elastin-like polypeptide is a biocompatible protein polymer that is used to protect attached cargo
from degradation, rapid renal clearance, and immunogenicity to prevent the transfer of cargo across
the placenta. A, Elastin-like polypeptide is modified with targeting agents or cell penetrating peptides
to enhance organ specificity or to mediate target cell uptake. Elastin-like polypeptide is also modified
with cargo therapeutic peptides, therapeutic proteins, or with reactive sites for covalent attachment
of small molecule drugs. B, Placental transfer of elastin-like polypeptide. Quantitative fluorescence
analysis revealed that the elastin-like polypeptide carrier accumulated highly in the placenta (red and
yellow) but did not penetrate into the fetal circulation after bolus injection or chronic infusion in a rat
pregnancy model.
Reprinted with permission from George et al.467
Ilekis. Potential placental molecular therapeutic targets. Am J Obstet Gynecol 2016.
ajog.org Obstetrics SupplementELP is an ideal drug carrier for several
reasons. Because of its origins in human
elastin, it is not recognized as foreign by
the immune system, does not induce an
inﬂammatory response or immunoge-
nicity, and is likely slowly broken down
into individual amino acids in vivo,
making it completely biocompatible.
Because the ELP sequence is encoded at
the DNA level, modiﬁcation of the
polymer sequence (to tune the polymer
size, to add reactive sites for drug
conjugation, or to fuse targeting agents,
therapeutic peptides, or therapeutic
proteins) is a matter of simple molecular
biology.462-464 Also, because it is protein-
based, ELP can be produced by recom-
binant expression in bacterial or
eukaryotic systems,459,460,465 and it is
easily puriﬁed by a nonchromatographic
procedure called inverse transition
cycling.460,466 This makes scale-up to
production levels that is required for
therapeutic development very feasible.
Finally and most importantly, because of
its large size, ELPs can protect small
peptide or drug cargo from rapid
degradation and extend their plasma
half-life and bioavailability.
Our strategy involves the use of a core
ELP biopolymer as a drug carrier; this
biopolymer is modiﬁed at its amino
and/or carboxy-termini with targeting
agents, cell-penetrating agents, peptide
or protein therapeutics, or reactive sites
for drug attachment (Figure 17, A). In a
recent study, we examined the pharma-
cokinetics and biodistribution of ELPs in
a rat pregnancy model. The ELP carrier
accumulated at very high levels in the
maternal kidney, liver, and placenta after
systemic intravenous infusion, but little
to no ELP crossed into the fetus after
either a bolus administration or 5 days of
continuous infusion (Figure 17, B).467
This study indicates that the ELP drug
carrier may be a powerful means of
sequestering fused therapeutics to the
maternal circulation and preventing fetal
drug exposure.
Mechanisms of symptom onset in pre-
eclampsia and potential therapeutic
interventions. Preeclampsia is a disease of
placental insufﬁciency that is rooted in a
poorly understood process of impairedspiral artery remodeling during early
placental development.468-470 Because
the molecular basis for this failed
remodeling is understood poorly and
because a robust biomarker to predict
patients who will become preeclamptic
is lacking, it is not yet practical to
design targeted therapeutics to correct
spiral artery remodeling and prevent
preeclampsia. However, preeclampsia
symptoms do not present until later in
pregnancy, and, unlike the initiating
factors in spiral artery remodeling, the
molecular pathways that lead to symp-
tom precipitation are much better un-
derstood. Therefore, now is the optimal
time to develop therapeutics that are
targeted to the progression of pre-
eclampsia with the goal of extending
pregnancies and improving fetal out-
comes.471,472 The overall goal of ourJULY 2016 Amapproach is to target the pathways that
lead to hypertension, impaired renal
function, neurologic complications, and
other components of the preeclampsia
syndrome in hopes of delaying the need
for induced delivery for as long as
possible; we aim to do so in a manner
that protects the fetus from exposure to
the therapeutic agents.
The molecular pathways that lead to
the symptom precipitation of symptoms
in preeclampsia are a consequence of
placental hypoperfusion and hypoxia.
In response, the hypoxic placenta re-
leases a multitude of factors that
affect the mother at nearly all organ
systems.473 Brieﬂy, the major players in
the progression of the preeclampsia
syndrome can be divided into 3 groups,
antiangiogenic factors, proinﬂammatory
factors, and inducers of ROSerican Journal of Obstetrics& Gynecology S33
FIGURE 18
Model for the role of antiangiogenic factors and inflammatory cytokines
in preeclampsia.
The ischemic placenta is known to be a source of the vascular endothelial growth factor antagonist
protein sFlt-1 and many proinflammatory cytokines. These factors cooperate with 1 another to
produce systemic inflammation and endothelial dysfunction in the mother, which is manifested
clinically in multiple organ systems. Illustrated are our proposed strategies for interfering with these
processes by either supplementing vascular endothelial growth factor or placental growth factor
levels by the administration of exogenous elastin-like polypeptide-fused proteins or by giving elastin-
like polypeptideestabilized inhibitors of NF-kB.
ELP, elastin-like polypeptide; NFkB, nuclear factor kappa-light-chain-enhancer of activated B cells; sFlt-1, soluble fms-like tyrosine
kinase; VEGF, vascular endothelial growth factor.
Adapted with permission from Bidwell and George.473
Ilekis. Potential placental molecular therapeutic targets. Am J Obstet Gynecol 2016.
Supplement Obstetrics ajog.org(Figure 18).470 These factors induce
endothelial dysfunction and systemic
inﬂammation in systemic vascular beds
of the maternal circulation that ulti-
mately lead to the clinical manifestations
of preeclampsia.
One of the major proteins produced
by the hypoxic placenta thought to drive
maternal preeclampsia symptoms isS34 American Journal of Obstetrics& GynecologysFlt-1. SFlt-1 levels were found to be
elevated dramatically in patients with
preeclampsia with a corresponding
reduction in the plasma levels of its
ligands-VEGF and PlGF.474 VEGF is
known to be important in endothelial
cell health, and its sequestration by sFlt-1
binding is hypothesized to lead to many
of the renal and vascular effects ofJULY 2016preeclampsia.475 This makes sFlt-1 one
of the major targets for preeclampsia
drug development. One strategy we are
using is to supplement VEGF levels by
administering an exogenously prepared
ELP-VEGF fusion protein.470 We have
previously found that VEGF signaling
activity is maintained after ELP
fusion,460 and our goal with this strategy
is to restore the angiogenic balance that
was lost when sFlt-1 production was
increased. In addition to the reduction of
systemic endothelial dysfunction, this
strategy might have the added beneﬁt of
increasing placental perfusion by
enhancing uterine or spiral artery blood
ﬂow. We are also examining a related
strategy of supplementing PlGF by
administering an ELP-PlGF fusion pro-
tein. This has the potential to be safer
and easier to dose strategy than direct
VEGF administration. The hypothesis is
that the exogenous ELP-PlGF will bind
sFlt-1 as well as the full length cell surface
receptor Flt-1,476 thereby displacing
VEGF andmaking it available to bind the
more active receptor VEGFR2. Because
sFlt-1 has no known signaling function
and VEGFR1 is much less active than
VEGFR2,477 supplementation of PlGF
may be less prone to side-effects
compared with the direct administra-
tion of VEGF.
Other major drivers of preeclampsia
symptoms include the chronic systemic
inﬂammatory response (exacerbated
by placental production of inﬂamma-
tory cytokines).478 The inﬂammatory
response in preeclampsia is known to be
mediated by tumor necrosis factor-a,479
proinﬂammatory interleukins,480 and
agonists of TLR signaling481 that is pro-
duced in the placenta and possibly by
systemic macrophages and/or endothe-
lial cells. A commonmediator of all these
inﬂammatory signaling pathways is the
transcription factor NF-kB. Another
strategy that we are exploring is the ex-
amination of NF-kB as a potential drug
target for preeclampsia. As a ﬁrst
attempt, we have generated an ELP-
delivered peptide inhibitor of NF-kB
signaling. The ELP fusion protects this
peptide from rapid renal clearance after
intravenous administration, enhances its
placental deposition over 30-fold relative
ajog.org Obstetrics Supplementto free peptide, and prevents its transfer
across the placenta (unpublished data).
We hypothesize that a maternally
sequestered ELP-fused NF-kB inhibitor
will be effective as an antiinﬂammatory
agent and may slow the progression of
preeclampsia.
Current opportunities. The use of ELP or
related macromolecular carriers to
prevent fetal drug exposure represents a
promising new strategy for drug devel-
opment for disorders of pregnancy.
As described earlier, we are using
ELP fusions with therapeutic peptides
or proteins targeted to pathways of
importance in preeclampsia, but this
strategy is not limited to proteinaceous
therapeutics or to preeclampsia. ELP is
amenable to fusion with small molecule
drugs, and other projects in our labo-
ratory are examining the ability of
ELP to prevent transfer of known-toxic
or teratogenic drugs across the placenta,
thus potentially opening the door
for safe use of drugs that currently
are avoided in the pregnant patient
population.
Future opportunities.Our current strat-
egy is to use the ELP system to intervene
in late gestation, with therapeutics that
are targeted to pathways of currently
known importance in preeclampsia.
Future work will expand this strategy as
the list of potential drug targets con-
tinues to grow. The ELP system is
adapted easily for the delivery of nearly
any type of therapeutic, so expanding
this strategy to target newly identiﬁed
causative pathways is highly feasible. We
view the ELP system as a platform for
maternal sequestration of therapeutics,
and its attractive properties as a drug
carrier make it a promising platform
to be applied for delivery of novel
therapeutics.
Scientiﬁc gaps. Although we are focused
on treating symptoms of preeclampsia
during late gestation, the ideal scenario
would be to intervene early in pregnancy,
during trophoblast invasion and
placentation, to prevent the onset of
preeclampsia. However, to do that, we
need to gain a better understanding ofthe causative factors that hamper proper
placental formation in preeclampsia,
and we need robust biomarkers to
identify patients who will experience the
disorder.
Another area that currently stands as a
hurdle to the development of therapeu-
tics for preeclampsia and other disorders
of pregnancy is the high level of risk
aversion when treating pregnant
mothers. This risk aversion is well justi-
ﬁed given the vulnerability of the patient
population, and we have to address these
risks by doing all we can preclinically to
ensure the safety of developmental
therapeutics. One strategy for this is to
prevent fetal drug exposure using drug
carriers, as described earlier. In addition,
we must also strive to ensure that our
therapeutics is not adversely affecting
normal placental function. To address
these issues, we must use the best pre-
clinical models at our disposal to study
placental drug transport, fetal exposure,
and drug effects on normal placental
function, and we must follow offspring
in our preclinical models to insure
normal physical, mental, and physio-
logic development. Only after collecting
robust data in these areas should we
attempt to begin testing in human
pregnancies. Although we should pro-
ceed with caution and use every means at
our disposal to ensure safety, we should
not let fear of doing harm stiﬂe innova-
tion in the development of diagnostics
and therapeutics for use in pregnant
patients.
Comment
Exciting research was presented at the
workshop in the area of placentation,
trophoblast migration, and spiral artery
remodeling. Research ﬁndings in these
areas will be critical for developing
future treatments and, ultimately, the
prevention of adverse pregnancy out-
comes of placental origin that include
preeclampsia and FGR. Knowledge of
the basic biology of trophoblast invasion
and spiral artery remodeling is critical to
understanding the cause of many preg-
nancy disorders; once the molecular
pathways that go awry are identiﬁed, it
will be possible to design therapeutics to
intervene in these pathways. However,JULY 2016 Amthis goal also elucidates another major
gap in the ﬁeld, the need for robust
biomarkers to predict the onset of the
disease early in pregnancy. Future
research in these areas will be critical for
ﬁlling this gap.
Data were also presented regarding
ongoing clinical efforts in the United
States and in Europe that are testing
novel interventions for preeclampsia and
FGR, including agents such as oral
arginine supplementation, sildenaﬁl,
pravastatin, a virally delivered VEGF for
local administration into the uterine ar-
tery to improve blood ﬂow and oxygen
supplementation therapy. Proposals
were also made to improve fetal health,
not by targeting maternal blood ﬂow but
by enhancing nutrient transport to the
fetus by modulating glucose and amino
acid placental transporters. Strategies
were presented for inhibiting mito-
chondrial dysfunction and oxidative
stress to improve placental health; the
roles of inﬂammation on both tropho-
blast function and in the advanced stages
of preeclampsia were discussed. The
roles of miRNAs and placentally derived
exosomes were discussed in the context
of their use for diagnostics and as drug
targets. These diverse pathways illustrate
many opportunities for drug interven-
tion. Although a number of potential
drugs to target these pathways are avail-
able and have been shown to be relatively
safe, the therapeutic beneﬁts of the ma-
jority of these drugs were never studied
in pregnancy. Hence, the safety and
pharmacokinetic proﬁles of these and
new therapeutics will need to be deter-
mined before their use in pregnancy. The
workshop discussed this aspect high-
lighting the unique pharmacokinetic
properties of pregnancy and the hurdles
and pitfalls of translating research ﬁnd-
ings into practice. The workshop
concluded with discussions of drug de-
livery during pregnancy. The potential
for using nanoparticles or protein bio-
polymers during pregnancy was pre-
sented, either to prevent fetal drug
exposure by blocking placental transfer
or to encourage drug delivery to the fetus
for in utero therapy by attaching agents
that actively are transported by the
placenta. The use of macromolecularerican Journal of Obstetrics& Gynecology S35
Supplement Obstetrics ajog.orgcarriers to prevent placental drug
transfer and fetal drug exposure repre-
sents an exciting new strategy for drug
development in pregnancy. Knowledge
that the fetus will not be exposed to the
therapeutic agent will open the door for
use of many drugs that currently are
avoided during pregnancy and will help
lessen the regulatory burden on drug
development for pregnancy-related
disorders.
The pregnant patient population
may be 1 of the most challenging co-
horts for which to develop drugs
because of concerns regarding drug ef-
fects on fetal outcome. Placental drug
transfer is a very real risk for many
small molecule drugs and even for
some actively transported biologics.
The potential for adverse fetal effects
not only represents a concern to preg-
nant mothers but also stiﬂes drug
development because of risk aversion
from the pharmaceutical industry and
from regulatory bodies. For many
therapeutics, we simply do not know
the risk to pregnant mothers or to their
developing offspring because preg-
nancy is most commonly excluded
from clinical trials. Of course, inter-
vention during this vulnerable devel-
opmental period must be approached
with extreme care. Wemust use the best
preclinical models at our disposal to
maximize the chance of elucidating
adverse drug effects for novel test
agents. Also, the use of drug delivery
strategies to target the placenta specif-
ically and/or prevent placental drug
transfer and fetal drug exposure is an
exceptionally promising method of the
development of new and safe thera-
peutics for use in pregnant women.
In closing, a major theme that clearly
developed from the workshop was that
we, as a scientiﬁc community, need to
stop thinking of pregnant women as a
vulnerable patient population for which
drug development should be avoided
and begin to appreciate our opportunity
to improve both maternal and fetal
health. This strategy could not only have
an immediate beneﬁt on pregnancy
outcome but also have a long-term
beneﬁt on the future health of the in-
fant, because recent evidence has made itS36 American Journal of Obstetrics& Gynecologyclear that the risks for many health out-
comes, which include the development
of cardiovascular diseases,482 metabolic
diseases,483 and cognitive developmental
disorders,484 just to name a few, are
strongly programmed by the in utero
environment. -
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